
















The Dissertation Committee for Kathryn Lauren Moncivais Certifies that this is the 
approved version of the following dissertation: 
 
 













Xiaojing John Zhang 
 










Presented to the Faculty of the Graduate School of  
The University of Texas at Austin 
in Partial Fulfillment  
of the Requirements 
for the Degree of  
 
Doctor of Philosophy 
 
 










Without the support and/or inspiration of these people I would not have this 
degree: Dr. Jonathan Zhang, Dr. Peppas, Dr. Georgiou, Dr. Roy, Dr. Ren, Dr. John Zhang, 
mom, Chris, James, Jessica, Laura, Yinan, Eileen, my wonderful undergrads: Jay, Wonjae, 
Young, and Tiffany, Dr. Saterbak, Dr. Oden, Tracy Volz, Jie, Gabby, Aiko, Liang, Hassan, 
Jessica, Laura, Coach Eike, Mrs. Ziegler, Mrs. Mueller, Coach Fletcher, and Mrs. Brown. 
 vi 
Novel Tools for the Study of Protein-Protein Interactions in Pluripotent 
Cells 
 
Kathryn Lauren Moncivais, Ph.D. 
The University of Texas at Austin, 2011 
 
Supervisor:  Zhiwen Jonathan Zhang 
 
Unnatural amino acids (UAAs) have been used in bacteria and yeast to pinpoint 
protein binding sites, identify binding partners, PEGylate proteins site-specifically (vs. 
randomly), and attach small molecule fluorophores to proteins. The process of UAA 
incorporation involves the manipulation of the genetic code, which is established by the 
proper function of aminoacyl tRNA synthetases (RSs) and their cognate transfer RNAs 
(tRNAs). It has been discovered that certain regions of RS proteins can either block or 
enable cross-species reactivity of RSs. In essence, a bacterial RS can function with a 
human tRNA by transferring the human CP1 region to the bacterial RS, and vice versa. 
This knowledge has been used to engineer a tRNA capable of recognizing a stop codon 
(tRNA*), rather than an amino acid codon, and a cognate RS capable of recognizing only 
tRNA* and no endogenous tRNAs. We have previously described the use of this 
methodology to engineer a UAA incorporation system capable of amber stop codon 
suppression in HEK293T cells. Since UAAs are so useful, and their use has now been 
enabled in mammalian systems, we applied UAA incorporation to pluripotent cells. 
Stem and pluripotent cells have been the focus of cutting edge research for years, but 
much of the work done on these cell lines is done in the ignorance of basic biological 
processes underlying differentiation, dedifferentiation, and tumorigenesis. In order to 
facilitate the study of these basic biological processes and enable more adept 
manipulation of differentiation, dedifferentiation, and tumorigenesis, the development 
and use of two separate UAA incorporation systems is described herein. The 
overarching goal of this project is to facilitate the study of protein-protein interactions 
in stem and pluripotent cells. Since we have also previously described the development 
of a mammalian two-hybrid system, the use of that system in pluripotent cells is also 
described. 
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Introduction: Specific Aims and Overview 
INTRODUCTION 
In recent years “stem cell” has become somewhat of a buzz word in the scientific 
community, probably owing to the leaps and bounds by which the field has grown in 
that same time period of time. The New York Times ran a story in 1998 about the 
infrequent but invaluable use of cryopreserved cord blood for treatment of leukemia, 
and since that time the incidence of stem cell based therapies has only increased (1). 
Stem cells have been successfully used as a treatment for anemia and multiple types of 
leukemia (2), and laboratory research has demonstrated their use in the treatment of in 
vivo models of diabetes (3), cardiac muscle disorders, Parkinson’s disease, and spinal 
cord injury (4, 5). Despite these encouraging results, stem cell transplantation 
techniques often result in the formation of benign tumors, a fact which is unsurprising in 
view of the proliferative nature of stem cells. Therefore, as with any new treatment 
modality, scientists must first characterize the behavior of these cells and why they 
develop benign tumors. Once that information is known, they can begin to capitalize on 
the advantages of stem cell based therapies.  
To characterize the causes of stem cell behaviors, research must be devoted to 
studying the protein-protein interactions (PPIs) and activation pathways involved in 
stem cell differentiation, dedifferentiation, and tumor formation. Without this 
knowledge, stem cell based therapies are simply cancer time bombs waiting to go off, 
but with it, they stand to change the face of medicine forever. Scientists may choose to 
use siRNA, co-precipitation, two-hybrid systems, genetic mutants, cross-linking, RT-PCR, 
ELISA, or any of a number of commonly used techniques to study PPIs in stem cells. 
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Unfortunately, all of the most common methods for studying PPIs, like those just 
mentioned, suffer from a few obvious disadvantages. Many of these techniques rely 
upon in vitro reaction conditions which poorly mimic the native environment of the PPIs 
under study, and they frequently measure PPIs indirectly and can produce positive 
results due simply to non-specific interactions of other proteins with those of interest. 
For a PPI investigational technique to successfully identify PPIs involved in the complex 
processes of differentiation, dedifferentiation, and cancer development, it would need 
to overcome some of these disadvantages and be able to capture weak, transient, and 
spatiotemporally specific interactions.  
In an attempt to fulfill this need for an advanced PPI investigational method, our 
lab has recently developed a novel technique for detection of protein-protein 
interactions in vivo in Escherichia coli (E. coli). An unnatural amino acid (UAA), L-3,4-
dihydroxyphenylalanine (L-DOPA),  bearing an orthogonal functional group not found in 
any natural amino acid was genetically encoded in the gene for the Staphylococcus 
aureus (S. aureus) virulence factor Sortase A (SrtA). E. coli cells expressing SrtA with L-
DOPA were lysed and subjected to cross-linking conditions which revealed that SrtA 
exists as a dimer in vivo(6). While other cross-linking methods do exist, they utilize 
functional groups which are found in more than one amino acid and therefore 
frequently occur more than once within any given protein. These types of cross-linkers 
work so well that they often cross-link random, non-interacting proteins, yielding a 
substantial amount of false positives. While scientists are certainly accustomed to 
verifying and re-verifying their results, in a field with as much forward momentum as 
that of stem cell research, it would be far more favorable to use more stringent 
screening tools in order to speed the rate at which dependable information is generated 
and thereby decrease the time differential between initial discovery of stem cell 
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cascades and the clinical application of the same. Our lab has previously demonstrated 
that L-DOPA does not randomly cross-link, and it will only cross-link when incorporated 
into the interacting surface of the protein(s) (6). Therefore L-DOPA generates 
information about both the existence and location of interaction. Since L-DOPA has 
these clear advantages over conventional cross-linking methodologies, it is a good 
candidate tool for elucidating stem cell PPIs. In the following chapters of this 
dissertation, the groundwork for using L-DOPA as a site-specific cross-linker in stem-like 
cells will be presented. 
Various UAAs have previously been incorporated into proteins in vivo in yeast 
and bacterial systems, and a few have been used in mammalian cells(7).The 
incorporation efficiency in mammalian systems is dramatically lower than in yeast or 
bacterial systems, and at the same time the background is higher. Due to the extreme 
difficulty associated with stem cell transfection, the system for site-specific 
incorporation of L-DOPA must be improved to make it a viable tool in stem cells. Our 
group previously used a Methanococcus jannaschii (M. jannaschii) tRNATyr/tryosyl-tRNA 
synthetase pair which suppresses an amber stop codon to incorporate UAAs. This M. 
jannaschii tRNATyr is recognized to some degree by unknown endogenous aminoacyl 
tRNA synthetases (RSs) in mammalian cells, and therefore produced a significant 
amount of background incorporation of random amino acids. While the system has 
been used in easily transfected cell lines like HEK293Ts, it was too crude to be used in 
stem cells. Substantial progress has been made in recent years in understanding how 
tRNAs are recognized by their cognate RSs, and many new tRNA sequences have been 
catalogued for a myriad of different species and amino acid specificities (8). Additionally, 
scientists have made great strides in understanding how RSs discriminate between their 
intended amino acid and all the rest and have successfully switched RS specificities for 
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both amino acids and tRNAs. Armed with that information and bioinformatics tools, this 
dissertation presents the optimization of a UAA incorporation system and its application 
in stem cells.  
In addition to improving the system for incorporation of UAAs in mammalian 
cells, it was also necessary to improve upon existing transfection methods for stem cells. 
In the past, calcium phosphate precipitation and electroporation were the most 
effective techniques for stem cell transfection. However both methods result in high 
levels of cell death and mediocre transfection efficiencies. Newly available commercial 
products like Fugene 6 and Fugene HD have demonstrated exceptionally high 
transfection efficiencies in some hard-to-transfect cell lines, and newly developed 
electroporation techniques have achieved high transfection efficiencies as well. 
Additionally, polyethylenimine has been recently demonstrated as a cost-effective 
alternative to expensive commercial reagents like Fugene 6 and Fugene HD. Presented 
in this dissertation is the investigation and optimization of the best of these techniques 
in order to develop a viable transfection protocol for hard to transfect cells.  
While UAAs can serve in a great many capacities beyond that of site-specific 
cross-linker, there are other PPI study methods which may also help in the delineation 
of differentiation/dedifferentiation/tumorigenesis pathways in stem cells. While they 
are plagued by a high incidence of false-positives, two-hybrid methods have worked 
well for some applications in the past. Since the our lab recently developed a novel two-
hybrid system capable of detecting weak interactions in HEK293T cells, its application in 
stem-like cells has been investigated in this work (9). A two-hybrid system for use in 
stem or stem-like cells, though imperfect, could be an asset in the toolbox for PPI 
investigation and thus is worth examination. 
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SPECIFIC AIMS 
The overall goal of this project is to develop and demonstrate the use of novel 
tools to study PPIs in proteins in stem cells which can be used in the future to 
elucidate signaling cascades involved in the processes of differentiation, 
dedifferentiation, and tumorigenesis. To accomplish that, the project has been broken 
down into three specific aims. 
 
Aim 1: Use rational design to create a new tRNA, aminoacyl synthetase, and TAG-
reporter protein system which exhibits lower background, increased orthogonality, 
and increased reporter gene expression in mammalian cells for subsequent use in 
stem cells.  
We hypothesized that bioinformatics tools could be used to develop an acceptor 
stem which was unrecognized by endogenous RSs. Human tRNA sequences for all amino 
acids were compared with all known tRNATyr sequences from any other organism, and a 
new tRNATyr was developed. In parallel with that, an E. coli tRNATyr was tested for 
orthongality. A new reporter gene was created by inserting an amber stop codon into a 
GFP gene optimized for mammalian expression. In this way we were able to create a 
more orthogonal tRNA, use its cognate synthetase, and switch to a reporter protein 
more easily expressed by mammalian cells, which afforded an efficient UAA 
incorporation system appropriate for use in stem cells. 
 
Aim 2: Overcome the stem cell transfection limitations of this system by (a) 
developing a transfection protocol capable of higher than previously published 
efficiencies, and (b) condensing the current triple plasmid system to a double or single 
plasmid system.  
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We hypothesized that current transfection methods were not effectively 
optimized for use in stem cells and that individual optimization of each technique or a 
combination of two or more techniques could dramatically increase transfection 
efficiencies in hard to transfect cell lines. (a) Fugene 6, Fugene HD, polyethylenimine, 
and electroporation were explored to determine the most efficient method for 
transfection of both single and double plasmids into P19 embryonal carcinoma cells. By 
optimizing these reagent based transfection methods outside the recommended limits 
of use it we were able to achieve higher transfection efficiencies than previously 
reported using the canonical methods. Further, by exploring extreme cell density, DNA 
concentration, and buffer conditions for electroporation we successfully exceeded the 
efficiency obtained using commercial products. We further hypothesized that 
decreasing the number of plasmids necessary for the system would allow for more 
efficient expression of the UAA incorporation system components. (b) After finding the 
maximum transfection efficiency for this cell line, the DNA constructs were altered such 
that the TAG-reporter protein and synthetase were expressed by a single bidirectional 
plasmid, and the tRNA was expressed by another plasmid.  
 
Aim 3: Demonstrate application of the optimized UAA incorporation system and the 
two-hybrid system in P19s, and demonstrate that the UAA incorporation system does 
not cause differentiation.  
We hypothesized that the tetracycline repressor based two-hybrid system could 
be used to detect PPIs in stem cells by introducing it to the system with the optimized 
transfection protocol developed in Aim 1. We used the two-hybrid system to detect a 
number of PPIs and found that strong interactions could be identified in this manner. 
We also hypothesized that the optimized UAA incorporation system would successfully 
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incorporate UAAs into proteins in P19s and would not cause differentiation. To test this 
theory, P19s were transfected with the components of a UAA incorporation system and 
immunostained for differentiation markers. It was found that the UAA incorporation 
system did not cause differentiation of this cell line and therefore could be useful in the 
study if PPIs in stem or stem-like cells. Cells from the same experiment were lysed and 
probed for UAA incorporation. 
 
OVERVIEW 
Chapter Two provides a broad overview of the background and significance of 
this work. Chapter Three discusses the lengthy process of developing a superior 
transfection method by optimizing a wide variety of methods and in one instance 
combining two. It reveals that a superior, consistent transfection method for P19s was 
developed and dramatically improved the outcome of all experiments in this work which 
involve transfection. Chapter Four details the development of a UAA incorporation 
system suitable for use in mammalian cells, while Chapter Five discusses the application 
of that system in P19s. Chapter Six gives a brief overview of the progress made on 
incorporating UAAs into proteins in P19s. Chapter Seven discusses development and use 
of a mammalian two-hybrid system, which was able to detect strong binding events. 
Finally, Chapter Seven discusses the broad conclusions which can be drawn from this 
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Background and Significance 
CURRENT TRENDS IN STEM CELL BASED THERAPIES 
A brief survey of scientific literature reveals more stem cell based therapies and 
lines of research than could be described in this short work. In fact a simple search of 
clinicaltrials.gov for “stem cell” reveals 1,619 active clinical trials involving stem cell 
based therapies. Some of the most exciting stem cell based therapies currently in use or 
development are those focused on spinal and nerve damage treatment. Fetal stem cells 
have been used in the treatment of cerebellar ataxia, a disorder of caused by 
dysfunction or absence of Purkinje cells in the cerebellar cortex. Several studies have 
found that transplanted embryonic stem cells (ESCs) engraft and migrate to the adult 
cerebellar cortex but do resolve the functional problems of cerebellar ataxia (1, 2). In 
contrast, Triarhou and colleagues have demonstrated that grafting the cells directly into 
the desired location allows the ESCs to engraft and form synaptic contacts which result 
in reversal of some symptoms of cerebellar ataxia (3). While these results in a mouse 
model are very exciting, their application in a human setting is sobering. A 2009 study 
published in PLoS Medicine describes a stem cell transplantation procedure which was 
used to treat a child with ataxia telangiectasia. Four years after the procedure recurrent 
headaches were the first sign of the spinal and cerebral tumors which resulted from the 
stem cell transplantation (4). Unfortunately the authors did not comment on the 
possible benefits of the procedure, instead focusing on the nature of the tumors and 
their implications for the field of stem cell research. However, the authors of this study 
echo the sentiments in this dissertation that the field of basic stem cell biology needs 
further advancement before treatments of this kind can be used safely and effectively.  
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Despite the clear risks of ESC transplantation based therapies, there are still a 
number of ongoing studies investigating this strategy for the treatment of a number of 
disorders, and some have gone so far as to genetically modify these cells prior to 
transplantation. Xi and colleagues used purified embryonic stem cell derived 
cardiomyocytes (ESC-CMs) in conjunction with mouse embryonic fibroblasts (MEFs) to 
treat an in vitro model of myocardial infarction (5). They found that combining the ESC-
CMs and MEFs allowed mechanical integration of the ESC-CMs and force transduction 
from the damaged tissue to the transplanted cells. Rizvanov et al transfected human 
umbilical cord blood cells (hUBCs) with a plasmid which simultaneously expressed 
vascular endothelial growth factor 165 (VEGF165) and human fibroblast growth factor 2 
(HFGF2) (6). The transfected hUBCs were then injected into presymptomatic 
amyotrophic lateral sclerosis (ALS) transgenic mice, which lead to development of 
astrocyte like cells. Since astrocyte dysfunction is a known component of ALS, these 
results are considered to be promising.  
No matter how many successful experiments are carried out in vitro or even in 
animal models of certain diseases, the problem of cancer development will still loom 
large in the field of stem cell therapies. Further compounding that problem are the 
ethical issues surrounding the use and obtainment of ESCs. In light of these issues, much 
work has been devoted to finding alternate sources of pluripotent cells. Some 
researchers have focused on more readily available sources of multipotent cells like 
mesenchymal stem cells (MSCs) while others have gone so far as to attempt to 
dedifferentiate adult cells into stem or progenitor cells and use them in place of ESCs. 
Researchers first seized upon the idea of using MSCs as differentiable and ultimately 
implantable tissue replacements due to their ready availability, ease of expansion, and 
lack of immune rejection risk.  In 2004 Alhadlaq and colleagues reported the 
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development of a human-shaped articular condyle using a polyethylene glycol (PEG) 
based hydrogel and rat bone marrow derived mesenchymal stem cells (7). MSCs were 
expanded in the presence of chondrogenic or osteogenic factors, suspended in the 
unpolymerized hydrogel solution, and then the cell + hydrogel solution was 
photopolymerized into the shape of a human mandibular condyle. The cell-seeded 
hydrogels were implanted in severe combined immunodeficiency (SCID) mice and 
harvested four weeks later at which point they exhibited the intended osteogenic and 
chondrogenic regions. While this work certainly serves as a proof of concept, the 
implants would need to be monitored for a much longer period of time in order to draw 
any conclusions about longevity of the state of differentiation of these cells as well as 
their mechanical and biological properties. Macchiarini et al took a similar but more 
organic approach to engineering an implantable replacement airway for a young woman 
with end-stage bronchomalacia (8). A human donor trachea was decellularized, cleared 
of MHC antigens, and then seeded with the epithelial cells and MSC derived 
chondrocytes. The seeded trachea matrix was incubated for 96 hours in a novel 
bioreactor which rotated 90 degrees every 30 minutes to ensure even distribution of 
growth medium. The engineered trachea replacement was then implanted and 
demonstrated no issues with host rejection despite the recipient not taking 
immunosuppressive drugs. Additionally, the recipient of the engineered trachea 
experienced almost immediate restoration of a functional airway. In addition to these 
successes, MSCs have been differentiated into insulin-producing cells in the search for a 
viable beta-cell replacement modality in the treatment of diabetes (9-11). Researchers 
have also used cord blood derived MSCs to create insulin producing cells, which 
reinforces the prudence of cryo-preserving cord blood (12). It has also been suggested 
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that MSCs could be used in cancer therapy since they naturally migrate toward tumors. 
They could be used as vehicles for anticancer gene delivery (13). 
It should be noted that in each of these cases in which MSCs have been used as a 
source of differentiable and later implantable cells, the differentiation methods 
employed are not based upon a global understanding of the underlying processes. 
Instead they are based upon the scientific body of work leading up to this point. In 
laymen’s terms, these differentiation processes are akin to a child who writes a letter to 
Santa every year and always gets the present at the top of their list. They are ignorant of 
the underlying process of gift procurement and delivery (i.e. their parents), but they 
depend upon their experience that writing a letter to Santa always yields the same 
results. While this is not necessarily the worst position for the state of research, it 
certainly leaves a lot of room for improvement. However, as can be seen below, 
exploitation of the knowledge that A leads to B in ignorance of what happens in 
between, can produce some very exciting results. 
On the dedifferentiation front, researchers have developed inducible pluripotent 
stem cells (iPSCs) using transcription factors known to play a role in pluripotency (14). 
Takahashi and Yamanaka used viral vectors to express Oct4, Sox2, Klf4, and c-Myc in 
adult fibroblasts, which successfully restored these cells to multipotency (15). A 
subsequent study using human somatic cells used Oct4, Sox2, Nanog, and Lin28 to 
induce pluripotency in a more clinically relevant manner (16).  
While the monumental nature of these studies cannot be denied, the amount of 
time, effort, and money that it took to complete them is almost as monumental as the 
work itself. Owing to the lack of basic biological knowledge of the processes of 
differentiation and dedifferentiation, each of these studies began by screening much 
larger libraries of transcription factors and the effects of numerous combinations of 
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these transcription factors of interest. In short, researchers started by generating basic 
biological information and applying it to the process of dedifferentiation. While they did 
discover cocktails of transcription factors which effectively induce pluripotency, there 
are still no answers as to why they induce pluripotency and what other effects these 
transcription factors may be exerting. Regardless of the state of ignorance of the global 
processes involved in dedifferentiation, these studies served as the jumping off point for 
a number of very interesting experiments. In response to concerns of the viral methods 
of pluripotency originally used, scientists began investigating non-viral induction 
methods. The use of plasmid DNA, protein treatment, and RNA-based methods have 
each accomplished successful induction of pluripotency in adult cells (17-19). 
Unfortunately the highest reported efficiency with which all pluripotency induction 
methods act is at the most 0.005% (20). This dismal induction efficiency can be 
attributed to incomplete knowledge of the underlying mechanisms of dedifferentiation 
and differentiation, a fact which scientists seem to comment about profusely without 
actually acting to change the situation (14). 
From the preceding information, one can draw a few conclusions. First of all, the 
field of stem cell research is flourishing. Second, stem cell research seems to be just on 
the cusp of developing incredibly useful, revolutionary, regenerative therapies for a 
number of diseases. Lastly though, and least excitingly, this field is lacking in 
fundamental, basic science knowledge of the molecular processes underlying 
dedifferentiation, differentiation, and tumorigenesis of pluripotent cells. While 
incredible tools and therapies may be developed in the absence of this knowledge, it 
cannot be argued that all of these therapies would be better, safer, and more accessible 
to the people they would most benefit if the blanks in our knowledge of the inner 
workings of these cells were filled. 
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PROTEIN-PROTEIN INTERACTIONS STUDIES IN STEM CELLS 
It is a well established fact that most embryonic stem cells (ECs) require 
leukemia inhibitory factor (LIF) in order to maintain pluripotency (21), which made the 
LIF mechanism of action one of the first targets of protein-protein interactions (PPIs) 
studies in stem cells. This section will focus on the methods employed to study PPIs in 
stem cells rather than the interactions themselves, because the overall aim of this 
project is to create and achieve proof of concept of tools which will facilitate the study 
of protein-protein interactions. Ersnt and colleagues used a combination of stable cell 
line development, immunoprecipitation, Western Blotting, mobility shift assays, 
antisense RNA, and nucleotide exchange assays to determine a few useful aspects of the 
LIF mechanism (21). First, it became clear that phosphorylation of the Src-related kinase 
Hck was an almost immediate effect of LIF stimulation, which was further corroborated 
by the investigation of the effect of a constitutively active form of Hck. Cells expressing 
the constitutively active form of Hck had less dependence on LIF for the maintenance of 
pluripotency. Further, inhibition of the expression of members of the Janus kinase (Jak) 
family increased the dependence of ES cells on LIF, implicating Jak family members as 
part of the signaling cascade involved in pluripotency maintenance. In 1999 (3 years 
later) the same group used an almost identical tool set to delineate the cytoplasmic 
domain of the cytokine receptor chains involved in maintenance of pluripotency via the 
LIF pathway (22). They found that the carboxy-terminus (C-terminus) of gp130 was 
necessary for transduction of proliferation signals in LIF treated cells, and they further 
refined this information by determining the location within the C-terminus without 
which pluripotency could not be maintained. It should be noted that both of these 
studies were completed by the same group, that there was a three year gap between 
these publications, and that the information generated deals specifically, as far as we 
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know at this point, with pluripotency. Differentiation, dedifferentiation, and 
tumorigenesis likely involve far more complicated and transient protein-protein 
interaction networks than pluripotency, and thus can be expected to require more 
intense study if they are to be delineated. 
Another popular PPI investigational technique is that of microarrays. Freemantle 
et al used the commercially available Human Unigene 1 Life microarray from Incyte 
Genomics, which is comprised of 9,128 independent clones, representative of 8524 
unique genes, to study retinoic acid (RA) mediated differentiation in human embryonal 
carcinoma cells (23). They identified a total of 57 genes which were up-regulated and 37 
genes which were down-regulated in response to RA treatment. It should be noted that, 
based upon the number of up-regulated or down-regulated genes and the total number 
represented in the microarray, at any given time less than 1% of the cDNAs studied 
were affected by RA treatment. This indicates that the number of proteins and 
transcriptional factors involved in RA mediated differentiation, and ostensibly other 
differentiation pathways, is very small. However, many proteins are known to have 
promiscuous interactions with multiple binding partners, so this does not mean that the 
total number of proteins and PPIs involved in these processes is the same size as the 
number of altered genes. Unsurprisingly, many of the upregulated genes in this study 
were already known participants in developmental pathways (i.e. transforming growth 
factor beta, Notch, Hedgehog, and Wnt). In contrast, many of the downregulated genes 
were involved in protein processing and turnover. While high throughput studies like 
this one generate a wealth of information, they do not give any reliable information as 
to which of the upregulated proteins is interacting with which other proteins. So it 
provides insight into which proteins are likely involved but does not reveal the 
molecular details of how they interact and achieve signal transduction. 
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P19 EMBRYONAL CARCINOMA CELLS 
While developing a tool kit for the study of PPIs in stem or pluripotent cells, it is 
crucial that an appropriate cell line be employed. An appropriate cell line for this 
endeavor would have the following characteristics: 1) Capable of differentiating into 
multiple cell types, 2) Transfectable, 3) Well established protocols for differentiation 
assessment, 4) Highly proliferative, 5) Requires minimal effort to maintain pluripotency. 
Admittedly, that list is almost unreasonable, but there are cell lines that have all of 
those characteristics. We have chosen P19 mouse embryonal carcinoma cells (P19s) for 
the work undertaken in this project; their history and qualifications, as per the previous 
list, are discussed below. 
Teratocarcinomas are germ cell tumors composed of embryonal carcinoma and 
teratoma cells and can form when early embryos are transplanted into ectopic sites (24, 
25). McBurney and Rogers transplanted a 7.5 day old embryo into the testis and then 
cultured the cells which arose from that procedure, eventually developing the P19 cell 
line (26). This cell line was remarkable at the time as it grew easily and quickly in culture 
in the absence of feeder layers or differentiation maintenance supplements like LIF. 
With many stem cell lines, cell density cannot surpass a certain level without initiating 
differentiation, but conveniently P19s do not exhibit this same behavior (27, 28). This 
property alone makes maintaining this cell line much simpler and less time intensive 
than culturing a cell line that requires a feeder layer and/or differentiates in response to 
confluency. McBurney and colleagues demonstrated that P19s could be differentiated, 
but they had to be both dense and treated with certain drugs in order to efficiently 
direct them toward a certain lineage (29). In response to nonlethal concentrations of 
either dimethylsulfoxide (DMSO) or retinoic acid (RA), P19s can differentiate to neuronal 
cells or a variety of mesodermal cells including cardiac and skeletal muscle (30-32).  
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As previously mentioned, cells must be cultured at high density and in non-tissue 
culture treated vessels in order for DMSO or RA induced differentiation to occur with 
any efficiency (32). To differentiate P19s using RA, cells must be aggregated and 
exposed to 3x10-7M RA for as little as four hours to induce irreversible differentiation to 
neuronal cell types (30). six days after RA treatment up to 85% of cells express neuronal 
markers (33). While other cell types do occur in RA treated P19 cultures, neuronal cell 
types are by far the most abundant (30). DMSO induced differentiation begins with 
aggregation as well and requires only 0.5-1% (v/v) DMSO in the culture medium (32). 
Within 7 days of DMSO treatment, cardiac muscle cells which often beat rhythmically 
can be found in culture, accounting for roughly one quarter of the total cells in culture. 
These cells express a number of proteins which indicate their similarity to embryonic 
tissue rather than adult tissue (34), which makes them a good candidate for the study of 
PPIs involved in normal cardiac development.  
In light of the many advantages P19 cells possess over their more totipotent 
peers, it is unsurprising that they have been used continuously since their discovery to 
study many aspects of development and differentiation (35-37). To investigate the role 
of bone morphogenic proteins (BMPs) in cardiac differentiation, P19s were transfected 
to over-express noggin, an inhibitor of BMPs (38). Noggin expression successfully 
prevented DMSO induced cardiac differentiation, but addition of BMP proteins to the 
media could restore cardiac differentiation. While DMSO may induce cardiac 
differentiation, it is not responsible for upregulation of BMP, and cardiac differentiation 
cannot proceed in the absence of BMP(38). In the same study as well as subsequent 
studies aimed at delineating the signals involved in DMSO induced differentiation of 
P19s, researchers were able to develop an incomplete picture of this process, shown in 





Similar experiments have been carried out with the end goal of defining the 
neural differentiation pathway activated by RA treatment in P19s. By overexpressing 
FoxA1, a known component of neural differentiation in P19s, and studying the 
expression of several other proteins in response to FoxA1 expression, Tan and 
colleagues were able to identify some of the downstream effects of RA induction (40). 
FoxA1 expression was followed by a dramatic and almost immediate decrease in 
expression of the pluripotency marker Nanog followed by a delayed increase in the 
expression of the neuronal protein Nestin (40). It was also found that siRNA knockdown 
 
Figure 2.1: DMSO induced differentiation pathways in P19 embryonal carcinoma cells. Gray 
lines or boxes indicate speculated relationships or proteins that are unconfirmed 
at this time. 
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of FoxA1 prevented the upregulation of both Nestin and sonic hedgehog (Shh) in 
response to RA induction. These results indicate that FoxA1 expression is necessary for 
neuronal differentiation in response to RA treatment, and Nestin and Shh are 
downstream targets of the FoxA1 differentiation cascade. 
In contrast to the action of FoxA1, Foxm1 expression is diminished during 
neuronal differentiation in response to RA (41). Knockdown of Foxm1 resulted in a 
corresponding decrease in expression of the well-known pluripotency marker Oct4, and 
overexpression of Foxm1 in P19s at day 4 of RA induced neuronal differentiation 
restored the expression of Oct4 as well as Nanog and Sox2, also well known 
pluripotency markers (41). The effect of Foxm1 knockdown was also assessed in 
teratoma formation, which yielded an interesting result: Foxm1 negative teratomas 
were limited in the lineages to which they could differentiate. Foxm1 knockdown caused 
spontaneous cardiac differentiation in vivo. This result begs for further investigation as it 
is one of few with the implication that the neuronal and cardiac differentiation 
pathways may involve some sort of molecular switch, most likely somewhere 
downstream of Foxm1. 
The preceding information points to several basic truths about the investigations 
of PPIs in P19s. First, these cells have proven highly useful in the last 30 years, and 
therefore represent a solid choice for development of new tools for the study of PPIs in 
pluripotent cells. Second, the information gleaned from these cells in that time period is 
woefully incomplete. Third and finally, the usefulness of these cells and their potential 
impact on regenerative and transplantation medicine demands that scientists find ways 
to more quickly and efficiently exploit the unique advantages of this cell line and others 
like it. 
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STEM CELL TRANSFECTION METHODS 
Stem cells have the potential to revolutionize the fields of medicine and biology, 
so it is unsurprising that scientists would be interested in transfecting them with 
exogenous DNA. In certain adherent cell lines, commercial reagents have been used to 
achieve close to 100% transfection efficiency, which is a monumental improvement over 
all techniques in use 20 years ago (unpublished data). Unfortunately, as is the case with 
most transfection methods, these reagents do not transfect stem cells as well as they do 
other cell lines. Because of this, most attempts at genetic manipulation of stem cells 
have utilized viral methods. Lentiviral transfection methods have achieved both high, 
stable gene expression and unmodified differentiability of infected cells (42, 43). While 
lentiviral and most viral methods yield superior results as compared to all other 
techniques, the difficulty and additional safety measures involved in producing the 
viruses prevents them from being the first choice for this project. However, they still 
represent a logical gene delivery vehicle, especially for investigations of the effect of 
single proteins or mutant proteins. The project presented within this dissertation 
involves the expression of two proteins and one exogenous tRNA. Because of that, the 
time it takes to use virus-based method in this endeavor may prove more costly than 
the results are worth. Thus, it will be investigated for efficacy and feasibility, but it will 
be quickly replaced with a simpler method if it appears to be more time consuming than 
its results can justify. 
Electroporation, liposomal, and non-viral, non-liposomal methods have been the 
most successful transfection techniques aside from viral based methods. Fugene 6 and 
Exgen500, both non-liposomal, non-viral reagents, have reportedly achieved 11% and 
16% transfection efficiency in stem cells, respectively. However Exgen500 did adversely 
affect both cell viability and rate of proliferation in comparison to Fugene 6 (44). The 
 21 
proprietary method of Nucleofection has been used to achieve between 50 and 60% 
transfection efficiency in endothelial cells (45) and a whopping 80% transfection 
efficiency in P19 embryonal carcinoma cells (Amaxa Literature). Since Nucleofetion is a 
proprietary form of electroporation, studies related to non-proprietary electroporation 
could shed some light on how to achieve the same level of transfection. It has been 
reported that high salt, high voltage electroporation conditions can achieve between 6 
and 10 fold better transfection efficiency than alternative methods (46).  
LABELED PROTEINS AND THEIR USES 
Green Fluorescent Protein (GFP) was discovered in 1962 by Shimomura, 
Johnson, and Saiga (47), and it is safe to say that this discovery revolutionized the in vivo 
and ex vivo study of proteins. In the near half century since its discovery, GFP has been 
transformed from an unknown greenish protein into a household name in biological 
science. In the following chapters, the use of an optimized form of GFP as a reporter 
protein will be discussed extensively, but one of the most frequent and successful 
applications of GFP has been as a fusion tag (48). Since the introduction of GFP as a 
fusion tag, researchers have attempted to increase the potency and decrease the size of 
fusion tags, because GFP was able to yield such a wealth of information about protein 
compartmentalization. In the following section, the uses and creation of protein tags 
will be discussed, as will their implications for the research presented in this 
dissertation. 
The labeling of proteins in mammalian cells allows researchers to quickly and 
easily determine a number of things. First, tagging proteins with a fluorescent moiety 
allows for the microscopic evaluation of localization of a single protein (i.e. nuclear 
versus endoplasmic reticulum), and adding two different fluorescent moieties to two 
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proteins can reveal valuable information about colocalization of proteins in unperturbed 
cells or during specific cellular processes. This type of experiment is fast and can provide 
information for the refinement of subsequent studies. Second, tagging proteins with a 
cross-linker can allow determination of PPIs and conformational changes in living cells. A 
protein of interest can be tagged with a cross-linker, and at the chosen time or perhaps 
under the conditions of interest to the researcher, cross-linking can be catalyzed and 
subsequent protein purification, and possibly mass spectrometry as well, can reveal the 
identity of the cross-linking partner. Protein tagging can also facilitate PPI investigation 
through fluorescence resonance energy transfer (FRET) (49, 50). Third, tagging proteins 
can allow for immunological detection of proteins for which dependable antibodies do 
not exist. One example of this phenomenon is histidine (His) tagging of proteins. His-
tagged proteins can be easily detected with commercially available antibodies directed 
against the His-tag rather than the protein itself. Fourth, proteins can be tagged to allow 
for easy purification. A His-tagged protein can efficiently bind nickel beads in a protein 
purification column, a technique which is incredibly frequently used by researchers in all 
biological fields. The fifth and final use of tagged proteins is to allow for chemical or 
post-translational modification. Tagged proteins can be selectively modified in a number 
of ways when certain functional groups are introduced, and site-specifically tagging said 
proteins allows the targeting of whatever modification is desired. Further, some tags 
can serve as pseudo post-translational-modifications (PTMs) and facilitate the study of 
the same (51). 
UNNATURAL AMINO ACIDS AND THEIR APPLICATIONS 
So-called unnatural amino acids (UAAs) are amino acid analogues which are 
unrepresented in the genetic code of most organisms. Because they are absent from the 
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genetic code, they present orthogonal functional groups to most systems, functional 
groups which can be specifically modified without interfering with other proteins 
necessary for function of the cell or organism under study (52). These functional groups 
have been used in a number of novel applications in recent years. Some UAAs are very 
similar to canonical amino acids but are heavier than their analogs. These UAAs can be 
extremely helpful in crystallography experiments. For example, methionine was 
replaced with selenomethionine in a protein, and that replacement facilitated 
crystallographic determination of the protein’s structure(53). 
A number of UAAs are small fluorescent molecules which are incredibly useful 
for protein tagging and visualization applications. Schultz and colleagues have used the 
small fluorescent UAA shown in Figure 2.2 to visualize nuclear localization of histones in 
Chinese hamster ovary (CHO) cells (52). This same type of UAA is known to exhibit high 
sensitivity to environmental changes which can be detected by excitation and emission 
spectra shifts (52). Mills et al successfully exploited this property, using a small 
fluorescent UAA to probe antibody-antigen binding (54). Summerer and colleagues 
employed dansylalanine in much the same strategy to detect folding/unfolding of 








Figure 2.2:  Small fluorescent 







Another popular application of UAAs is in cross-linking of interacting proteins. 
Since many PPIs are transient and/or weak, covalent cross-linking is necessary to 
directly assess biologically relevant interactions, especially if those interactions are to be 
assessed in vivo. Two UAAs have been successfully used in this endeavor by multiple 
groups. L-3,4-dihydroxyphenylalanine (L-DOPA) has been incorporated into proteins in 
multiple organisms and cross-linked to their interacting partners. L-DOPA was 
genetically encoded in the gene for the Staphylococcus aureus (S. aureus) virulence 
factor Sortase A (SrtA). E. coli expressing SrtA with L-DOPA were lysed and subjected to 
cross-linking conditions which revealed that SrtA exists as a dimer in vivo (56). This same 
UAA has also been used to increase the affinity of a peptide-based antibody by cross-
linking the peptide-antibody to its target on a nitrocellulose membrane (57). 
Benzoylphenylalanine (Bp-Ala) is a photoreactive cross-linker which covalently attaches 
to binding partners upon irradiation by certain wavelengths of light (52). Bp-Ala has 
been incorporated into the adapter protein Grb2, which is known to function in Ras 
signaling (58). When co-expressed in CHO cells with the EGF-receptor and subjected to 
photocrosslinking conditions, Bp-Ala containing Grb2 irreversibly linked to EGF 
receptors (58). It should be noted that L-DOPA mediated cross-linking is usually carried 
out with lysed cells, whereas Bp-Ala cross-linking can be done in living cells. This is 
important, because in vivo cross-linking combined with fluorescent probes can generate 
a wealth of information very quickly, whereas techniques which assess cell lysate rather 
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than live cells generate less information which may be less biologically relevant due to 
lysis conditions and their effect on PPIs. 
 
The last and final application of UAAs to be discussed in this dissertation is as a 
non-fluorescent probe of protein structure and function in living cells. Since UAAs often 
differ from their canonical counterparts in the size and/or shape of their functional 
groups, they can be used to investigate the mechanical role of amino acids in wild type 
proteins. For example, o-methyl-L-tyrosine was used to investigate a proposed model of 
voltage dependent K+ channel inactivation in neurons (59). Tyr19 was replaced with o-
methyl-L-tyrosine in the K+ channel Kv1.2, and its effect on activation/inactivation of 
Kv1.2 was assessed. It was found that introducing the bulky side chain of o-methyl-L-
tyrosine slowed the inactivation by a factor ranging from five to seven in comparison to 
the wildtype Kv1.2 channel (59). This method could be applied to the mechanism of 
action of many ion channels as well as a number of other conformational 
change/protein structure investigations. 
MECHANICS OF UNNATURAL AMINO ACID INCORPORATION 
The process of UAA incorporation is much like that of the incorporation of 
natural amino acids. Each canonical amino acid within a protein is represented by a 
series of codons, each of which consists of a specific three nucleotide sequence. Each 
codon represents only one amino acid, though each amino acid is represented by more 
than one codon. In addition to the codons for amino acids, there are codons 
representing ‘START’ and ‘STOP’ locations for protein translation, effectively directing 
the ribosome where to begin and end translating a protein. Once a gene has been 
transcribed from DNA to messenger RNA (mRNA), it can be translated by the ribosome 
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complex. As shown in Figure 2.3, the ribosome is the location at which tRNA with 
previously covalently attached amino acid(s) base pairs with mRNA, bringing the correct 
amino acid into the ribosome active site and allowing it to be attached to the growing 
peptide chain. For this process of DNAmRNAprotein to work correctly, the fidelity 
of the original genetic code must be maintained by RSs, which catalyze the attachment 
(aminoacylation) of amino acids to tRNAs. RSs must therefore distinguish both the 
correct amino acid and any of a set of isoacceptor tRNAs which bear the anticodon for 
their cognate amino acid. Therefore UAAs can be incorporated by hijacking the 













There are three basic methods by which this process of hijacking the 
endogenous cellular machinery can be accomplished. 
1. In vitro aminoacylation 
TRNAs can be produced, purified, and aminoacylated with the UAA of 
Figure 2.3:  Protein synthesis basics 
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interest in vitro. They can then be introduced to cells in a variety of ways. 
Once in the cells, they will be incorporated into proteins by endogenous 
ribosomes just as any other aminoacylated tRNA would be. 
 
2. Random Incorporation 
Cells can be starved of a natural amino acid then exposed to the UAA 
analog to that natural amino acid. They will then misincorporate the UAA 
indiscriminately in locations where the natural amino acid should have 
been incorporated. This technique alters all expressed proteins in a cell, 
not just specific intended proteins. 
3. Site-specific Incorporation 
A mutant RS and tRNA are produced by the cell as an addition to its 
existing genetic code. This RS-tRNA pair can then incorporate the 
intended UAA at specific locations within proteins designated by the 
researcher. 
Each of these techniques has been successfully employed in mammalian cells, and each 
has its own set of strengths and weaknesses which will be discussed in the following 
sections. 
IN VITRO AMINOACYLATION OF UNNATURAL AMINO ACIDS IN LIVING CELLS 
Monahan and colleagues developed a system for UAA incorporation in 
mammalian cells through in vitro aminoacylation of amber suppressor tRNA (60). Amber 
suppressor tRNA is any tRNA bearing the anticodon for an amber stop codon, whose 
DNA sequence is TAG. This stop codon has been used extensively in the field of UAA 
incorporation because it is the least frequently used stop codon in mammalian cells and 
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therefore will result in the least number of perturbations of endogenous protein 
expression. After aminoacylating amber suppressor tRNA in vitro, mRNA coding for the 
protein of interest, in this case a GFP-based reporter protein or a nicotinic acetylcholine 
receptor (nAchR), was co-electroporated with the aminoacylated tRNA into CHO cells. 
Successful incorporation of the UAA was evidenced by a shift in the acetylcholine dose 
response curve of cells expressing the UAA-receptor in comparison to those expressing 
the wildtype receptor (60) .  
Six years after the Monahan manuscript was published, a new version of in vitro 
aminoacylation appeared in the literature. Instead of aminoacylating an amber 
suppressor tRNA, they used a tRNA with a frame-shift anticodon. In effect, a tRNA with a 
four base (versus the traditional three base) anticodon was used to translate proteins in 
Xenopus oocytes (61). The same in vitro aminoacylation approach was used, but instead 
of electroporating, the oocytes were simply injected with mRNA for the protein of 
interest and the aminoacylated frameshift tRNA. Since the chosen UAA in this 
investigation was a small-molecule fluorescent UAA, the success of incorporation was 
assessed via fluorescence microscopy (61). 
While Monahan and colleagues achieved proof of concept of the idea of in vitro 
aminoacylation for UAA incorporation in living cells, Pantoja and colleagues 
demonstrated proof of concept of aminoacylation of frameshift tRNAs for UAA 
incorporation in living cells. Each investigation resulted in high incorporation efficiencies 
as well as quick results (60, 61). However, these experiments are short-lived and can 
only be used to study phenomenon occurring over small time frames. Since the cells 
studied are not producing the machinery with which to incorporate the UAA, they will 
only incorporate it as long as they have aminoacylated tRNA to use. Once that tRNA is 
exhausted, UAAs will no longer be incorporated. Additionally it should be noted that in 
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vitro aminoacylation for UAA incorporation in mammalian cells can be quite 
cumbersome without the appropriate transfection technology. Monahan and colleagues 
used a microelectroporator which required total electroporation volumes of less than 5 
µL and a total amount of aminoacylated tRNA+DNA of 32.5 µg in that same volume (60). 
With a conventional electroporator which uses a volume between 100 and 400 µL, that 
same experiment would take between 0.65 and 2.6 milligrams of aminoacylated 
tRNA+DNA per condition. That is an enormous amount of DNA alone, but coupled with 
the necessary amount of aminoacylated tRNA, the materials costs alone for an 
experiment of that size would be prohibitive. As will be discussed in Chapter 3, large 
amounts of DNA are necessary for successful electroporation with conventional 
electroporators, but clearly, with the proper equipment, the raw amounts of DNA 
necessary for a successful experiment need not be so unreasonably gargantuan. So 
while in vitro aminoacylation can provide quick, effective, UAA incorporation, it is not 
the most versatile of techniques and is not an accessible technology for researchers 
without the necessary equipment. 
RANDOM INCORPORATION OF UNNATURAL AMINO ACIDS IN LIVE CELLS 
The Tirrell group at the California Institute of Technology has pioneered the use 
of random incorporation of UAAs into proteins in live cells (62-64). The general protocol 
involves depleting cells of the natural analog of the UAA to be used, treating them for a 
defined period of time with the UAA, and finally labeling the UAA with a fluorescent 
probe for visualization (63). Beatty et al successfully used this strategy to label proteins 
expressed during defined time points with different colors of fluorophores with reactive 
groups specific to the UAAs used (63). Though useful, this technique is imperfect. First, 
the labeling technique requires treatment with CuSO4, which is toxic for most cells. 
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Second, it was found that cells with azidohomoalanine (Aha) incorporated and then 
reacted with the fluorescent probe bodipy-630-alkyne were indistinguishable from 
control cells unlabeled with Aha when using confocal microscopy, though fluorescence 
activated cell sorting (FACS) was able to differentiate between the two (63).  
Using the same UAA, Aha, Beatty and colleagues were able to develop a more 
biologically inert labeling technique. Instead of copper catalyzed addition, azid-alkyne 
cycloaddition was used to label randomly incorporated UAAs in rat fibroblasts (62). 
Dimethylaminocoumarin (DMAC) was conjugated to a variety of cyclooctyne acids to 
create coumarin-cyclooctyne conjugate molecules capable of labeling Aha in live cells 
(62). Rat fibroblasts were depleted of methionine then labeled with Aha for four hours. 
Cells were then incubated with coumarin-cyclooctyne conjugates to afford fluorescently 
labeled Aha containing proteins. Confocal microscopy and FACs were used to confirm 
the presence of coumarin in these cells. Cell viability assays were also performed to 
assess the impact of the coumarin-cyclooctyne labeling method on cell survival, which 
was negligible (62).  
Song and colleagues actually took this technology one step further by developing 
a fluorescent tetrazole-based probe capable of photo-crosslinking to an alkene bearing 
UAA (65). Homoallylglycine (HAG) was used as an analog for methionine in Hela cells 
previously deprived of methionine. Cells were lysed and tetrazole probes added to the 
lysate immediately before irradiating lysates with 305 nm light for ten minutes. 
Denaturing sodium-dodecyl-sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
buffer was added to fluorescently labeled cell lysates, they were separated via SDS-
PAGE, and fluorescence was assessed in the gel. It was found that 1 mM HAG resulted in 
efficient labeling of all proteins synthesized in the presence of HAG, and this 
fluorescence peaked twenty four hours post HAG addition (65). One very interesting 
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thing completed by this group and not others was a mass spectrometry analysis of the 
percentage of methionine sites actually occupied by HAG. A His-tagged protein was 
expressed under HAG labeling conditions, purified, digested, and analyzed via nanoLC-
tandem mass spectrometry. It was found that each methionine site had a different HAG 
occupancy with no real pattern to which sites were more or less frequently labeled, and 
the frequency varied among sites between 42.3% and 83.7% (65). It was also found that 
proteins could be labeled in live cells by simply incubating them in tetrazole-probe 
containing buffer for ten minutes, then irradiating them with 302 nm light for five 
minutes. Using FACS, it was determined that HAG labeled cells were exhibited an eleven 
fold increase in mean fluorescence over non-HAG labeled cells. 
The novelty and scientific elegance of the preceding studies cannot be argued, 
however this technique is not yet viable for the study of PPIs. Rather, it is an excellent 
tool for the study of temporally regulated global protein expression studied. 
Researchers can quite easily label proteins expressed during a given time period, and 
slight modifications of the experiments in the preceding paragraphs could generate a 
substantial amount of useful information. For instance, one can imagine that stem cells 
in the process of differentiation could be labeled during the first 2 days of 
differentiation, globally, with a UAA capable of blue fluorescent labeling. On day three, 
they could be labeled with a UAA capable of red fluorescent labeling. After labeling with 
the second UAA, cells could be conjugated with their fluorescent labels, lysed, and their 
protein expression profiles examined by simple SDS-PAGE. A series of blots could be 
completed by probing, stripping, and re-probing the same membrane with antibodies 
for proteins of interest in the differentiation process. By comparing the fluorescence 
and western blot images it would be possible to compare proteins highly expressed 
during the early phase of differentiation with those expressed during later phases. 
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Obviously the time points of two days with one label and the third day with another 
could be changed, even to a number of hours, as Beatty and colleagues saw efficient 
labeling within that period of time (63). While the technique of random UAA 
incorporation is not necessarily viable for the study of PPIs as it stands, it may yet find a 
place in the study of differentiation, dedifferentiation, and tumorigenesis.  
SITE SPECIFIC INCORPORATION OF UNNATURAL AMINO ACIDS IN LIVE CELLS 
The last and final type of UAA incorporation to be covered in this dissertation, 
and the one which this project has chosen to utilize, is site-specific incorporation of 
UAAs. This particular method of UAA incorporation is perhaps the most involved, but as 
will be discussed in the following pages, it may also be the most useful for the study of 
PPIs in mammalian cells. In order to site-specifically incorporate UAAs into proteins in 
living cells, a codon must be appropriated to stand for the UAA, an RS must be 
developed which specifically recognizes the desired UAA, and a tRNA must be 
developed which is recognized by the RS and not by any endogenous RSs in the cell line 
to be used. Basically, a site-specific UAA incorporation system must have the following 
characteristics in order to function as intended: 
1) UAAs must be incorporated in response to a unique or unused codon. 
2) The tRNA bearing the unique codon must not be recognized by endogenous 
synthetases. 
3) The UAA specific RS must recognize only the intended tRNA and UAA, and it 
must discriminate against canonical amino acids and endogenous tRNAs. 
While such a UAA incorporation system has been accomplished in bacteria and 
yeast (51, 56, 66-68), no global system satisfying all three requirements has yet been 
developed for use in multiple cell types. Thus individual researchers have developed 
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methods of evolving RSs and tRNAs with specificity for each other and various UAAs of 
interest (66). First, researchers start by selecting a tRNA and RS pair from a different 
organism than the one in which they want to incorporate the UAA. The tRNA from that 
organism is then mutated at locations known to be involved in tRNA specificity 
(discussed below) such that there is little to no reactivity of that tRNA with the 
endogenous RSs in the organism in which the tRNA will be used. The chosen RS is then 
mutated at residues selected based upon the crystal structure of a similar RS, and a 
library of mutant RSs is built. The RS library is then subjected first to a round of positive 
selection in E. coli, which only allows cells expressing an RS capable of aminoacylating 
the previous developed tRNA with the UAA of interest to survive. Cells which survive the 
positive selection are then subjected to negative selection in which cells containing RSs 
that aminoacylate the previously developed tRNA with a canonical amino acid survive. 
Colonies which die in the negative selection round are the ones that do not charge the 
tRNA with a canonical amino acid, and they are picked from a replica plate and 
expanded for further analysis (66). This technique and variations of it have been used to 
develop a number of tRNA-RS pairs capable of incorporating a wide variety of UAAs into 
proteins in a number of cell types (55, 56, 66-70), but those of the greatest importance 
for this work are the ones which have been applied to mammalian cells. These types of 
systems are unique in that they cannot be evolved in the cells in which they are 
intended to function. Mammalian cells are not capable of the high-throughput library 
screening employed in positive and negative selection necessary for tRNA-RS 
development. Thus, most researchers have chosen to evolve these pairs in yeast and 
then transfer them to the mammalian cell line of their choice.  
One of the earliest examples of this methodology being applied to protein 
translation in mammalian cells came from Sakamoto et al in 2002 (71). A Bacillus 
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stearothermophilus amber suppressor tRNA (tRNAB.stear) was used with a previously 
evolved E. coli tyrosine tRNA synthetase which recognizes tRNAB.stear and charges it with 
the UAA 3-iodo-L-tyrosine (71). A reporter protein was created by adding an amber stop 
codon to the sequence of cyan fluorescent protein (CFP), and expression of CFP was 
assessed visually. As another measure of UAA incorporation, a separate reporter protein 
based upon Ras was used in two forms: wildtype and amber stop codon mutated. Cells 
expressing both the wildtype and amber stop codon mutated versions of Ras were 
cultured in media containing 0.3 mM 3-iodo-L-tyrosine, and UAA incorporation was 
assessed via western blot and mass spectrometry (71). It is important to note that the 
highest expression level achieved in this study was about one fourth the level of 
expression seen in the wildtype protein, indicating that while UAA incorporation is 
possible in mammalian cells, it is inefficient. Examination of the western blots produced 
in this experiment may lead one to conclude that UAA incorporation is only slightly 
inefficient, but this would be an erroneous conclusion as the surface area of cells used 
for the amber stop codon mutated Ras gene was five times the surface area used for 
wildtype Ras protein purification (71). Despite the obvious inefficiency of UAA 
incorporation in this case, it did serve as a clear proof of concept that exogenous tRNAs 
and RSs could be functionally expressed in mammalian cells. 
Another instance of site-specific UAA incorporation in mammalian cells was 
published in 2005. Zhang et al used a slightly different methodology to incorporate 5-
hyrdoxytryptophan (5-Htrp) into proteins in mammalian cells (72). Instead of utilizing 
the amber stop codon, as many have done in the past, Zhang and colleagues designed a 
system that incorporated 5-Htrp into proteins in response to an opal stop codon with 
the sequence TGA (72). Cells were co-transfected with opal suppressor tRNA, an 
exogenous RS specific for 5-Htrp, and reporter protein with an opal suppressor stop 
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codon inserted into the middle of its DNA sequence. 5-Htrp incorporation was assessed 
via western blot and mass spectrometry, which confirmed the incorporation of 5-Htrp 
into the reporter protein at the opal stop codon (72). Since 5-Htrp exhibits substantial 
absorbance at 310 nm, the absorbance spectra of wildtype and 5-Htrp containing 
proteins were compared. This revealed an eleven fold increase in 310 nm absorbance of 
the 5-Htrp containing protein in comparison to the wildtype protein. Additionally, it was 
demonstrated the 5-Htrp can be redox cross-linked by applying a positive potential to a 
solution of 5-Htrp containing protein (72). Of note is the assertion by the authors of this 
study that “the exact mechanism of the protein crosslinking mediated by [5-Htrp] is not 
yet clear” (72). It seems that the field of stem cell research is not the only one willing to 
use incomplete information in order to further their scientific endeavors. 
My colleagues and I have recently developed and demonstrated the use of a new 
method for development of a UAA incorporations system in mammalian cells (69). Both 
tRNAs and RSs have specific domains within their structure that have been implicated in 
species as well as UAA specificity. These exact identifiers will be discussed in greater 
detail below. Our system uses rational design to manipulate these identifiers and quickly 
create orthogonal, functional UAA incorporation systems for use in mammalian cells. A 
previously evolved Methanocaldococcus jannaschii (M. jannaschii) tRNA-RS pair served 
as the jumping off point for this system. It is known that the wildtype M. jannaschii 
tRNA shares some species specific identifiers with human tRNA and thus would not be a 
good candidate for use in mammalian cells without alteration of these identifiers (69). 
To create tRNA orthogonality, the species specific identifiers in M. jannaschii tyrosyl 
tRNA (tRNAMJtyr) were mutated to match those of E. coli tRNA (tRNAEctyr). Once that 
mutation was introduced, the tRNAMJtyr no longer functioned with its native RS. To 
restore RS function, the tRNA recognition site of M. jannaschii tyrosine-RS (RSmjtyr) was 
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replaced with that of the E. coli tyrosine-RS (69). The success of this cut-paste approach 
was demonstrated by successful expression of two separate TAG mutated genes. In the 
initial development phase, when a quick readout of tRNA-RS function was desired, a 
TAG mutated eGFP gene was used. This allowed visual assessment of orthogonality and 
function. Once this was established, another TAG mutated protein was overexpressed in 
HEK293T cells and assessed via western blot. While no quantification of suppression 
efficiency was done, the authors concluded that suppression efficiency was 
approximately 20% of wildtype expression of un-TAG-mutated proteins. This efficiency 
will be important in the final stages of the work presented in Chapter Six. Of note is the 
fact that a UAA was not incorporated in this work, but rational design of a mammalian 
UAA incorporation system was demonstrated by amber stop codon suppression (69). 
From this study and the studies mentioned in the preceding paragraphs it is clear that 
site-specific UAA incorporation can be achieved in mammalian cells, though it is unclear 
how versatile this technology may prove to be.  
DETERMINANTS OF TRNA SPECIES SPECIFICITY 
All tRNAs have the same basic cloverleaf structure shown in Figure 2.4, which 
indicates that RS discrimination of desired versus undesired tRNA cannot be based upon 
secondary structure alone. Though the anticodon is involved in recognition, its effect is 
frequently less than that of the acceptor stem nucleotides, specifically nucleotides 1 and 
72 (73, 74). Wakasugi et al have demonstrated that switching the human wild type (WT) 
tRNATyr from C1:G72 to G1:C72 completely abolishes aminoacylation by human RSTyr 
(75). A subsequent study demonstrated that mutation of M. jannaschii tRNATyr from 
C1:G72 to G1:C72 prevents aminoacylation by RSmjTyr(14). It has also been shown that 
the eukaryotic RSTyr from Pneumocystis carinii is dependent upon the 1:72 nucleotide 
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identity (76). So at least in the case of tRNATyr, the 1:72 base pair is able to confer or 
block aminoacylation in a species specific manner. In addition to the 1:72 base pair, E. 
coli RSs for Met, Cys, Trp, Val, Ile, Glu, Gln, and Arg are known to bear identifiers within 
their acceptor stems further than just the 1:72 pair (77).  It has been posited that these 
interactions are based on a destabilization (or lack) of the 1:72 base pair which confers 
flexibility on the acceptor stem (77, 78). Thus, previous research has clearly 
demonstrated that it is possible to confer or knock down tRNA species specificity by 













Though the effect of the anticodon sequence is less dramatic than that of the 
acceptor stem nucleotides, they do serve as identifiers for some tRNA/RS pairs. Since 
the anticodons used in UAA incorporation are necessarily different than those used for 
canonical amino acids, mutant UAA tRNAs with mutations only in the anticodon usually 
display some loss of activity as compared to their wildtype predecessors. Kobayashi et 
Figure 2.4: tRNA Secondary Structure 
 38 
al. solved the crystal structure for the M. jannaschii tRNATyr/ RSmjTyr pair, revealing that 
RSmjTyr does use the anticodon in tRNA identification (79). As shown in Figure 2.5, RSmjTyr 
interacts with the anticodon, but only at the 286th residue, and the only interaction is 
between RS-D286 and tRNA-G34. When creating an amber suppressor tRNA from M. 
jannaschii tRNATyr, G34 is mutated to C34, switching the 34th nucleotide from a purine 
to a pyrimidine base. This switch effectively increases the distance over which 
interaction must occur between nucleotide 34 and D286, which explains the decrease in 
activity between wildtype and amber suppressor M. jannaschii tRNATyr. Fortunately, 
mutations in the cognate RS can accommodate this anticodon mutation, but those will 
be discussed in the following section. Based upon the preceding information, an amber 
suppressor tRNA can be designed for use in a mammalian system by designing a tRNA 
sequence with a non-mammalian 1:72 nucleotide pair and acceptor stem sequence. 
  
Figure 2.5:  Crystal structure of M. jannaschii tRNA and RSTyr demonstrating interaction between 
nucleotide G34 and residue D286 (PDB 1j1u) 
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DETERMINANTS OF AMINOACYL-TRNA SYNTHETASE SPECIFICITY 
In 1999 Schimmel and Steer identified an RS whose unique properties make it a 
perfect candidate for mutation and use with UAA incorporation (80). Each species 
carries genes for the RSs of most, if not all, of the 20 canonical amino acids, the protein 
products of which are organized into two classes (81). Class I RSs are defined by a 
Rossman nucleotide binding fold and highly conserved HIGH and KMSKS motifs, while 
the class II RSs are characterized by three highly conserved sequence motifs within a 7 
stranded beta structure + 3 alpha helices (82). The RS identified by Schimmel and Steer 
is the previously mentioned class I tyrosyl RS (RSmjTyr) from the archaebacterium M.  
jannaschii. This RSmjTyr includes the characteristic Rossman fold and HIGH and KMSKS 
motifs, but it lacks a C-terminal portion of the protein implicated in E. coli  (83) and 
Bacillus stearothermophilus  RSTyrs (84-86) as interacting with the anticodon (77) region 
of tRNA. Since mutation of anticodon nucleotide U36 to G36 only yielded a 6 fold 
decrease in aminoacylation of G36-tRNA versus wildtype, Schimmel and Steer suggested 
that RSmjTyr does not directly interact with the anticodon of its cognate tRNA. As 
previously mentioned, Kobayashi and colleagues have demonstrated that RSmjTyr does 
interact with the anticodon, but in a different manner than other class I RSs (79, 80). As 
previously mentioned, mutation of the anticodon of M. jannaschii tRNATyr from G34 to 
C34 increases the distance over which the interaction between anticodon and RSmjTyr 
must occur. To offset the decrease in aminoacylation activity created by this mutation, a 
series of mutant RSmjTyr enzymes were created by mutating D286 to residues with a 
larger functional group than aspartic acid. In this way, the distance between C34 and 
residue 286 could be decreased. Ultimately it was found that mutation of D286 to 
arginine increased aminoacylation of the amber suppressor tRNA by 8 fold, achieving 
22% of the activity of the wildtype M. jannaschii tRNATyr/RSmjTyr pair (79). The preceding 
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work has established that it is possible to dramatically increase amber suppressor tRNA 
recognition by mutating D286 of RSmjTyr to R286. 
As previously mentioned, nucleotides 1 and 72 can confer or knock-down 
aminoacylation in a species specific manner. This indicates that the acceptor stem 
nucleotides interact with their cognate RS. One group investigating the role of 
nucleotides 1 and 72 in RS recognition successfully located the region within the RS 
responsible for that interaction. Wakasugi et al. used chimeric proteins to demonstrate 
the region within class I RSTyrs responsible for discrimination of nucleotides 1 and 72 
(75). An E. coli RSTyr was engineered to carry an N-terminal segment of the human 
enzyme, called connective protein 1 (CP1) (75).The aminoacylation activity of this 
chimeric enzyme (Figure 2.6, E. coli RSTyrEHE) was compared to that of the wild type (E. 
coli RSTyr) enzyme in aminoacylating either C1:G72 tRNA or G1:C72 tRNA, revealing that 
the chimeric enzyme could aminoacylate the C1:G72 tRNA but not the G1:C72 tRNA, 
shown in Figure 2.6 (75). By sequence comparison, the chimeric EHE enzyme is ~90% 
homologous with E. coli but was able to aminoacylate tRNA with human 1:72 
nucleotides and not the tRNA with E. coli nucleotides in the same position. This result 
suggests that the CP1 region of RSTyrs is capable of conferring species specific 
recognition of nucleotides 1 and 72 on chimeric proteins. Since the RSmjTyr investigated 
by Schimmel and Steer can readily accommodate anticodon mutations, and the CP1 
regions of RSTyrs can be switched out to confer species specificity according to 1:72 
nucleotide identities, we engineered M. jannaschii tRNA/ RSmjTyr system in which the 
mutated tRNA acceptor stem was unrecognized by mammalian cells, and the RS was 
given a CP1 region which recognized the mutated tRNA. The development of this system 
is described in full detail in Chapter Four, and its application to UAA incorporation in 




Figure 2.6:  E. Coli and human wildtype RSTyrs and EHE chimeric E. coli enzyme with 
human CP1 region; Aminoacylation of C1:G72 versus G1:C72 tRNAs by 
EHE chimeric RS, adapted from Wakasugi et al (75). 
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A TWO-HYBRID SYSTEM FOR USE IN STEM CELLS 
Since the aim of this entire project is to facilitate the study of PPIs in stem cells, 
an attempt at the use of a two-hybrid system was a logical addition to the work as a 
whole. A two-hybrid system is an elegant method for assessing PPIs in vitro and has 
been successfully applied to high throughput studies of PPIs (87). The basic design of a 
two-hybrid system consists of a reporter gene under the control of a modular 
transcriptional activation domain. Proteins are fused to two separate parts of the 
transcriptional activators, and PPIs are detected by expression of the reporter protein 
(87). Two-hybrid systems were initially used in yeast, owing to their adaptability to high 
throughput screening of two-hybrid libraries (88). However, in terms of clinical 
relevance, a two-hybrid system which directly screens PPIs in mammalian cells would be 
more advantageous, though at this time it would be incapable of easy high-throughput 
application. Two-hybrid systems have previously been converted for use in mammalian 
cells, but they were little more than simple transfers of the yeast system into 
mammalian cells (89) and frequently suffered from high background expression of 
reporter gene. My colleagues developed a mammalian two-hybrid system which 
improved upon previous versions, yielding lower levels of background and detecting 
weak interactions (90). 
The system developed by my colleagues, a tetracycline-repressor based 
mammalian two-hybrid system (tr-M2H), is based upon the highly active tetracycline 
repressor (TetR), a dimeric transcriptional regulator which binds specifically to the tet 
operator (TetO) to inhibit expression of a downstream gene. It was developed by 
modification of the commercially available Tet-Off® Advanced Inducible Gene 
Expression System (Clontech, Mountain View, CA).  The Tet-Off system is composed of 
the full length TetR C-terminally fused to three transcriptional activation domains from 
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the herpes simplex virus VP16 (90). TetR-VP16 fusion protein dimer allows the TetR 
dimer to bind the Tet-Responsive-Element (Tre) while the VP16 domain recruits 
transcriptional machinery.  In the trM2H system, the TetR c-terminal dimerization 
domain (alpha8-alpha10) has been replaced with bait and prey molecules, shown in 
Figure 2.7. When bait and prey proteins interact, the reporter protein, GFP in this case, 
is expressed. This system was successfully used to assess interactions of peptide pairs 
with binding constants ranging from 0.99 nM to 55 µM (90). HEK293T cells were 
transfected with the components of the tr-M2H system and imaged using a fluorescence 
microscope 48 hours after transfection. Cells were harvested, lysed, and reporter 
protein expression was assessed via western blot. Both the fluorescence images and 
western blots confirmed that peptide pairs known to interact with each other resulted 
in expression of the reporter protein, while non-interacting pairs did not cause 
expression of the reporter protein (90). These results lead us to conclude that the 
system may be appropriate for use in stem cells as it exhibits very low background and 
high sensitivity. As part of the body of work represented in this dissertation, we 









 Figure 2.7: Design of tr-M2H 
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By applying the body of knowledge previously generated by our group and 
others in the field of UAA incorporation systems as well as our own investigations of 
stem cell transfection techniques, this dissertation discusses attempts to transfer UAA 
incorporation systems into the stem cell environment and thereby facilitate the study of 
basic biological processes in these cells. The tr-M2H system’s application to the stem cell 
environment will be discussed briefly. The ultimate goal of this research is to speed the 
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Transfection Optimization in P19 Embryonal Carcinoma Cells 
INTRODUCTION 
Recent advances in the field stem cell research and therapy make it an attractive 
scientific problem for many researchers. In Chapter Two a brief overview of stem cell 
based therapies was discussed. This included an implanted tracheal graft that had been 
cellularized with the patient’s own cells (1) as well as tissue engineered articular 
condyles (2). There have also been cases of embryonic stem cells (ESCs) being 
transplanted from a donor to a disease model recipient, and some of these cases 
resulted in disappearance or improvement of some of the disease related symptoms (3, 
4). However, in some cases of ESC transplantation, including the one case of 
transplantation of ESCs into a human being, cancer can develop from the transplanted 
cells (5). With the current successes in the field of stem cell science, one can only 
imagine the therapies that could result from a more controlled, successful manipulation 
of stem cell behavior. To that end, this dissertation will discuss the development and 
implementation of tools for the study of protein-protein interactions (PPIs) in stem cells.  
In Chapter Two unnatural amino acid (UAA) incorporation was discussed as a 
means of studying PPIs in living cells, as was the tetracycline-repressor based 
mammalian two-hybrid system (tr-M2H). In order to successfully apply either of those 
systems to stem cells, a method must first be established for introduction of foreign 
DNA to these cells. Obviously, this is not the first line of research to attempt transfection 
of stem cells, therefore we started by investigating the methods used in the literature 
for stem cell transfection and designed our optimization experiments from there.  Since 
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P19 embryonal carcinoma cells have been widely used, there are several previous 
examples of transfection in this cell line.  
The earliest transfection experiments in P19s used either calcium phosphate 
precipitation or electroporation as their method of choice (6), but commercial reagents 
and proprietary electroporation based technologies have replaced them in recent years. 
Despite the advent of new ‘better’ technologies, viral transfection methods continue to 
be the most effective if not the most widely used. In 1992 Schmidt et al used a retroviral 
system to transfect P19s with a gene encoding c-src (7). Though they did not report 
measuring transfection efficiency directly, western blots of the desired protein products 
confirmed successful transfection and expression of detectable levels of protein (7). 
There is one fundamental difference between the goals and requirements of the 
Schmidt project and those of the project discussed in this dissertation: This project 
requires expression of two separate proteins and a tRNA. This means that viral 
transfection methods require much more preparation and time for this project than for 
those investigating expression or knockdown of a single gene. Thus, we chose to 
investigate non-viral methods before investigating viral methods for simplicity’s sake. 
In other work in our lab, HEK293T cells are routinely transfected with Fugene6 
and FugeneHD, each of which achieve close to 100% transfection efficiency in this cell 
line when used at the appropriate confluency. Thus it was convenient when Tan and 
colleagues published their work in which they used Fugene6 to transfect two separate 
DNA constructs into P19s (8), effectively giving us scientific license to use the materials 
already present in the lab. They too did not comment on the transfection efficiency of 
Fugene6, but it is noteworthy that they also used an adenovirus based transfection 
method for more protein intensive components of their work (8). In contrast to the 
preceding studies which do not include quantitative measurements of transfection 
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efficiency, Lonza’s Amaxa® Cell Line Nucleofector Kit provides readily accessible 
information regarding its success in transfecting P19s (9). This documentation includes 
images of transfected P19s expressing green fluorescent protein (GFP) along with the 
assertion that the transfection efficiency is higher than 80% (9). The images do not seem 
to represent 80% transfection efficiency, but fluorescence activated cell sorting (FACS) is 
more sensitive than fluorescence microscopy. So perhaps the image did not capture as 
much information as FACS. Regardless, even 50% transfection efficiency would be 
remarkable. Thus, Nucleofection seemed like a good method to test. Unfortunately, the 
Nucleofector is prohibitively expensive, and each transfection requires the use of a kit, 
further adding to the cost of this system. In light of this and the preceding information, 
we chose to test and optimize Fugene6, FugeneHD, and electroporation to start. We 
eventually tested a lentiviral transfection method as well. 
MATERIALS AND METHODS 
Cell Lines and Routine Cell Culture 
P19 embryonal carcinoma cells were obtained from American Type Culture 
Collection (ATCC). Cells were routinely maintained in Alpha-Mem (HyClone, Logan, UT) 
with 10% (v/v) fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 
nonessential amino acids (Sigma-Aldrich, St. Louis, MO) in a humidified incubator at 37° 
Celsius with 5% CO2 atmosphere. Cells were passaged every 1-3 days at a ratio between 
1:4 and 1:20. For passaging, cells were rinsed in phosphate buffered saline (PBS) (Sigma-
Aldrich, St. Louis, MO), incubated with  0.5% trypsin (Gibco, Invitrogen, Carlsbad, CA) for 
3-5 minutes, and centrifuged to pellet. Cells were then resuspended in complete media 
(as described earlier in this paragraph) and seeded into clean flasks with fresh media. 
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DNA Constructs 
The plasmid pEGFP-N1 was obtained from Clontech (Mountainview, CA). 
Fugene6 and FugeneHD Transfection  
Fugene6 and FugeneHD were obtained from Roche (Switzerland) and used 
according to directions. Previous experiments had shown that a ratio of 2 µL Fugene(6 
or HD) to 1 µg DNA was the most effective, so that ratio was used for all experiments. 
Complexes were formed in Opti-mem (Gibco, Invitrogen, Carlsbad, CA). All transfection 
experiments were done in the absence of antibiotics, and they were also done while the 
cells were in complete media with 10% FBS. Media was changed 24 hours after 
transfection, and every 24 hours thereafter until experiments were completed.  
Electroporation 
Cell densities were previously optimized. Instrument parameters were then 
optimized using the previously determined cell density. The combinations of parameters 
tested are shown in Table 3.1. From there, several total amounts of DNA were tested to 
find the best DNA concentration. In preparation for electroporation, cells were 
harvested using the same procedure as used for passaging, washed once in PBS, spun 
down, and resuspended in PBS. Cells were counted using a hemacytometer. Cell-DNA 
mixtures were made in Eppendorf tubes and then transferred to electroporation 
cuvettes with a 2 mm gap (Fisher Scientific, Waltham, MA). Cell-DNA mixtures were 
incubated on ice for no less than 5 minutes and no more than 15 minutes before 
electroporation, and they were kept on ice after electroporation for at least 3 minutes 
before plating. Cell-DNA mixtures were electroporated using a Bio-Rad Gene Pulser with 
capacitance extender and pulse controller (Bio-Rad, Hercules, CA) using the settings 
shown in Table 3.1. After electroporation (and previously mentioned short ice 
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incubation), cells were resuspended in complete media and plated in tissue culture 
vessels of the appropriate size (Corning, Lowell, MA). Media was changed 24 hours post-







Hybrid FugeneHD + Electroporation Transfections 
A modified version of Roche’s FugeneHD protocol was used for the hybrid 
transfection procedure. Instead of 50 µL of diluent per µg of DNA, 25 µL of diluent was 
used per µg of DNA. To ensure clarity of the procedure, the detailed protocol for 
transfection of 15 µg of a single construct will be discussed. Assuming the concentration 
of DNA is 1 µg/µL, the following protocol would be used. First, PBS is added to an 
eppendorf tube such that the final volume of PBS + DNA + FugeneHD will be 25 uL/ug 
DNA. In this case that is 330 µL of PBS. Then 15 µg of DNA is added to the PBS, followed 
by 30 µL of FugeneHD. The tube is closed securely, vortexed, and incubated while cells 
are harvested. P19s at 80-90% confluency are harvested from a single T-75 flask, 
washed in PBS, spun down, and resuspended in 900 µL of PBS. 300 µL of the cell solution 
is then aliquotted into an eppendorf tube and spun down. Once the supernatant has 
been aspirated from the eppendorf tube of P19s, the FugeneHD complexes should have 
been incubating for about 15 minutes. Once the FugeneHD complexes have incubated 
Table 3.1: Initial Electroporation parameters 
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at room temperature for at least 15 minutes, the P19 cell pellet in the eppendorf tube is 
resuspended in Fugene complexes and transferred to an electroporation cuvette. 
Electroporation is then completed as described for protocol D in Table 1. 
Calculation of Transfection Efficiency 
Transfection efficiency was calculated by determining the percentage of green 
pixels in each fluorescent image. Images were converted to monochromatic images in 
Adobe Photoshop. The magic wand tool was set to a tolerance of 5 and used to select 
the non-fluorescent part of the image. Transfection efficiency was defined as 
(fluorescent pixels/total pixels)*100. 
Fluorescence Imaging 
GFP expression was assessed 24 hours post-transfection and every 24 hours 
thereafter (until experiments concluded) via fluorescence microscopy using a Nikon 
Eclipse TE2000-S microscope with a FITC HyQ filter (Chroma, Rockingham, VT). 
RESULTS AND DISCUSSION 
Figure 3.1 shows the transfection efficiencies calculated from P19s 24 hours post 
transfection, and Figure 3.2 shows the fluorescent images from which those efficiencies 
were calculated. Transfection efficiency steadily rose as the amount of DNA was 
increased, up to 4.5 ug, after which point increasing the amount of DNA used resulted in 
lower transfection efficiency. Overall, transfection efficiencies varied between 1.5% and 
24.4% for Fugene6 transfection. Morphologically there is little difference between 
Fugene6 transfection conditions, but as can be seen in Figure 3.2, cells are small and 
rounded in all conditions. This indicates that Fugene6 has a negative impact on 
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Figure 3.1:  Efficiency of Fugene6 transfection of P19 embryonal carcinoma cells, 
























Figure 3.2:  P19 embryonal carcinoma cells expressing GFP 24 hours after transfection 






P19s transfected with FugeneHD maintained much healthier morphology, as can 
be seen in Figure 3.3. Figure 2.3also indicates that 5 µg of DNA transfected using 
FugeneHD results in the highest transfection efficiency achieved by either Fugene6 or 
FugeneHD. Figure 3.4 further corroborates that data. Interestingly, Figure 3.4, which 
shows transfection efficiencies calculated from the fluorescent images shown in Figure 
3.3 indicates that Fugene6 transfection efficiency for equivalent amounts of DNA 
outperforms FugeneHD until the amount of DNA surpasses 3 µg, at which point 
FugeneHD clearly yields higher transfection efficiencies. For FugeneHD, transfection 











Figure 3.3:  P19 embryonal carcinoma cells expressing GFP 24 hours after transfection 

















Figure 3.4:  Efficiency of FugeneHD transfection of P19 embryonal carcinoma cells, 
assessed 24 hours post-transfection. 
Fluorescent images of cells transfected using the electroporation parameters 
detailed in Table 1 are shown below in Figure 3.5, and the calculated transfection 
efficiencies for each of those conditions is shown in Figure 3.6. Overall transfection 
efficiencies for electroporation with the parameters detailed in Table 3.1 ranged from 
6.8% - 74.1%. However, the brightfield images in Figure 3.5 demonstrate that the 
mortality rate for each of these conditions is dramatically different. The best conditions 















Figure 3.5:  P19 embryonal carcinoma cells expressing GFP 24 hours after transfection 
by electroporation protocols detailed in Table 2.1. Brightfield images are on 
top of the fluorescent images of each condition. Each condition is clearly 
labeled with the name of the protocol used (A-D). 
Parameter set H did yield the highest transfection efficiency of the initial 
electroporation experiments, and it corresponds to transfection efficiencies commonly 
achieved in HEK293Ts (unpublished data). Unfortunately, the mortality rate of this 
protocol precludes its use as a transfection technique for the purposes of this project, as 
it would not produce enough live cells to use for protein expression assays. On the other 
hand, parameter set D achieved 42.4% transfection efficiency and, by visual inspection, 
excellent cell viability. After completing the Fugene6, FugeneHD, and electroporation 
experiments A-H, electroporation with parameter set D represented higher transfection 
efficiency than both Fugene methods and the best combination of transfection 
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efficiency, cell viability, and impact on morphology of all the electroporation protocols. 














Figure 3.6:  Efficiency of electroporation based transfection of P19 embryonal 
carcinoma cells using parameters detailed in Table 2.1, assessed 24 hours 
post-transfection. 
Figure 3.7 shows P19s electroporated using parameter set D and various 
amounts of DNA. As can be seen from those images as well as the transfection 
efficiencies calculate from them, shown in Figure 3.8, increasing the amount of DNA to 
100 µg dramatically increased the transfection efficiency without negatively impacting 
cell viability. The brightfield images for these experiments are not shown, because all 






Figure 3.7:  P19 embryonal carcinoma cells expressing GFP 24 hours after transfection 
by electroporation protocol D from Table 2.1 with various amounts of DNA 















Figure 3.8:  Efficiency of electroporation based transfection of P19 embryonal 
carcinoma cells using parameter set D from Table 3.1 and various amounts 
of DNA, assessed 24 hours post-transfection. 
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As shown in Figure 3.8, the 100 µg condition achieved a remarkable 73.8% 
transfection efficiency. At this point, we considered that we had found the best possible 
transfection technique for this cell line and began using it to test the UAA incorporation 
system in P19s. Fortunately we continued running eGFP positive controls for all of those 
experiments, because we learned that the instrument parameters, cell density, and 
amount of DNA were not the only factors in the success of this technique. Another 
critical factor is the amount of time between when cells are living happily in culture to 
when they are electroporated, and the amount of time between electroporation and re-
plating is also critical. Several representative positive controls are shown in Figure 3.9. 
While analyzing what could be the underlying causes of the stark differences between 
transfection efficiencies obtained during protocol development (Figure 3.7) and those 
obtained while attempting to implement the UAA incorporations system, it became 
clear that the only real difference was the number of conditions in each experiment. 
Experiments done in developing the protocol involved, at the most, nine conditions 
whose sole difference was the amount of a single DNA construct used, while 
experiments done with the UAA incorporation system involved 8 conditions at a 
minimum, and each of those conditions used different amounts of DNA and different 
numbers of at least four different constructs. The protocol itself was fine, but the 
amount of time between passaging cells, electroporating, and replating them was 
exerting a strong negative influence on transfection efficiency. To test this theory, cells 
were harvested from two flasks and were not counted. DNA was pre-aliquotted into 
eppendorf tubes, ready to receive cells as soon as they were passaged, washed, and 
resuspended in PBS. Each T-75 flask was used for three different conditions. Thus the 
amount of time necessary for the whole electroporation process was dramatically 
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reduced. As can be seen in Figure 3.10, this change brought transfection efficiencies 








Figure 3.9: P19 embryonal carcinoma cells expressing GFP 24 hours after transfection 
by electroporation protocol D from Table 3.1 with various amounts of DNA 










Figure 3.10:  P19 embryonal carcinoma cells expressing GFP 24 hours after modified 
transfection by electroporation protocol D from Table 3.1 with various amounts 





Though the alterations made to the electroporation protocol yielded 
transfection efficiencies high enough to use for UAA incorporation efficiency, they used 
milligrams of DNA for each experiment, which became problematic toward the end of 
this project. In an effort to finish the necessary experiments with a limited amount of 
DNA, we tried to recreate the phenomenon of Nucleofection. Presuming that the name 
was a combination of the words nucleus and transfection, we posited that 
Nucleofection had somehow achieved direct delivery to the nucleus via electroporation. 
As far as we know both Fugene methods and electroporation are simply methods of 
getting DNA past the lipid bilayer and not necessarily into the nucleus. However, if a 
liposomal based reagent could be delivered into the cytosol whole, then it may be able 
to cross the nuclear membrane and deliver DNA directly to the nucleus. Thus we chose 
to combine electroporation with FugeneHD. It is impossible at this stage to comment 
with any certainty on whether DNA actually was transferred directly to the nucleus or if 
the complexes were delivered to the cytosol whole. However, Figure 3.11 shows 
fluorescence microscopy images of cells transfected with electroporation + FugeneHD, 
and it is clear from these images that they achieve transfection efficiencies as high as 
the previous electroporation alone protocol. In contrast to electroporation alone, this 
protocol uses approximately 1/4th the amount of DNA per condition and resulted in far 
more stable electroporation results. In all of the electroporation experiments, it became 
clear that the time constant τ for each electroporation event was indicative of the 
success of transfection as well as mortality rate. FugeneHD in combination with 
electroporation consistently resulted in time constants below 30, which was indicative 
of consistently successful transfection and low cell death. Prior to that, each experiment 
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was done with an n of at least three to ensure that one of the three repeats would 






Figure 3.11: P19 embryonal carcinoma cells expressing GFP 24 hours after transfection 














Figure 3.12: Efficiency of hybrid FugeneHD + electroporation method of transfection of 
P19 embryonal carcinoma cells. 
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As is evidenced by the transfection efficiencies in Figure 3.12, combining 
FugeneHD with electroporation yielded higher transfection efficiencies than 
electroporation alone. In comparing electroporation with FugeneHD or Fugene6 alone it 
is important to keep in mind the amount of cells used in each case. Each electroporation 
condition uses approximately 75 cm2 of cells at 85% confluency while FugeneHD and 
Fugene6 use 9.6cm2 of cells at 60% confluency. A simple calculation indicates that each 
electroporation condition transfects approximately 11 times the number of cells that a 
FugeneHD or Fugene6 condition transfects. Meaning that the best FugeneHD adherent 
cell transfection method, which used 5 µg to transfect a single well in a 6-well plate, 
would require 55 µg of DNA to transfect the number of cells in an electroporation 
condition but would only transfer DNA to 35% of those cells. In contrast to that, 
FugeneHD + electroporation used only 25 µg to transfer DNA to 83.5% of the same 
amount of cells. Thus, FugeneHD + electroporation is the most efficient means of DNA 
transfer for large quantities of cells. Since UAA incorporation systems usually achieve 
about 20% of the expression level of wildtype proteins (10-12), a large number of cells is 
necessary to obtain enough protein for western blot, UAA incorporation assays, and 
mass spectrometry. Therefore the hybrid FugeneHD + electroporation method is the 
most appropriate method to use for UAA incorporation systems in stem cells.  
Each transfection method tested could be optimized to achieve transfection of at 
least 24% of the cells in a condition. While this level of transfection may be high enough 
for some applications, it is too low for something like site-specific UAA incorporation. 
Combining the efficacy of FugeneHD with that of electroporation yielded a hybrid 
transfection method capable of transfection efficiencies on par or in excess of other 
methods tested while using a fraction of the DNA. In experiments where the amount of 
DNA is not an issue, it may be more useful to use straight electroporation, like protocol 
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D from Table 3.1. This method of transfection is capable of high efficiency DNA transfer, 
but requires milligram levels of DNA and is not the most efficient in terms of 
transfection efficiency per µg of DNA. Since parts of the work presented in this 
dissertation were done in a research environment in which DNA was unlimited, this 
protocol was used for some experiments. However, when DNA was available in limited 
quantities, the hybrid FugeneHD + electroporation technique was used to achieve 
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An Unnatural Amino Acid Incorporation System for Mammalian Cells 
INTRODUCTION 
Chapter Two briefly discussed tRNA and aminoacyl-tRNA-synthetase (RS) 
specificity. In the following pages, the background information pertinent to engineering 
a tRNA/RS pair will be discussed in detail, beginning with the basic concepts of the 
genetic code and protein translation. With that information in mind, the application of 
those concepts to the creation of an unnatural amino acid (UAA) incorporation system 
for use in mammalian cells and then stem cells will be discussed. 
The Genetic Code and Protein Synthesis 
All genetic information is represented at the molecular level by DNA, but that 
information must be translated before it presents itself as proteins, cells, organisms, 
physiological phenomena, or behavioral modifications (1). Therefore all biological 
processes are dependent upon the fidelity of the genetic code as it is represented at the 
level of DNA. Since the focus of this work is on protein-protein interactions (PPIs), the 
most important part of this process is the basic idea of DNA translation to protein. This 
process is a multiple-step process, each of which has several mechanisms for 
maintaining the faithful representation of DNA at the protein level. 
Each of the twenty canonical amino acids is represented at the DNA level by a 
sequence of three nucleotide bases, called a codon. Each codon only represents one 
amino acid, but each amino acid can be represented by several codons; there are 
codons for both STOP and START translation signals. The first step in the process of 
converting DNA to protein is transcription. In this process, RNA polymerase ‘reads’ DNA 
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in the nucleus and creates a strand of messenger RNA (mRNA) representative of the 
DNA. In some eukaryotic cells, there can be post-transcriptional modifications like end-
capping and intron splicing which occur before mRNA is transcribed to protein. In any 
case, when the final mRNA product is produced, it can then be transcribed by a 
ribosome in the cytosol. 
As previously mentioned, each amino acid is coded for by a number of codons at 
the DNA level, so a ribosome must have some method of reading those codons and 
converting them from nucleic acids to the proper amino acid. The bridge between those 
two points in the process of protein translation is aminoacylated tRNA. Each tRNA has a 
region called the anticodon which bears the complementary sequence to its intended 
amino acid’s codon. In this way, a tRNA bearing an amino acid can come into the 
ribosome, base pair with the correct codon, and then allow attachment of the correct 
amino acid to the growing peptide chain. The process of aminoacylated tRNA base 
pairing with mRNA as it is read by the ribosome and amino acids being added to 











Figure 4.1: Translation of mRNA to protein within the ribosome. 
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Figure 4.1 includes the protein translation concepts most pertinent to UAA 
incorporation systems, but it is missing one very important part of the concept: charging 
of tRNA with the correct amino acid. Ribosomes do not actually discriminate between 
codon and amino acid; they do not have a proofreading mechanism based upon the 
mRNA codon and amino acid match. Instead they depend upon the tRNA anticodon 
base pairing with its cognate mRNA codon and being preattached to the appropriate 
amino acid. This means that maintenance of the genetic code is achieved prior to the 
ribosome’s role in protein translation at the point of tRNA aminoacylation. Therefore 
aminoacyl-tRNA synthetases (RSs), which conjugate amino acids to tRNAs, are 
responsible for maintaining the fidelity of the genetic code. RSs catalyze amino acid 
attachment to tRNAs (aminoacylation) in a two step reaction, shown in Figure 4.2. If an 
amino acid is attached to a tRNA bearing an anticodon intended for a different amino 
acid, then the protein for which this tRNA is used will not be produced as it is coded at 
the DNA level. It is this very property of protein translation and maintenance of the 









The UAA incorporation system developed and implemented in this work 
intervenes at the level of tRNA aminoacylation to reprogram the genetic code such that 
Figure 4.2: Two step aminoacylation of tRNA by RS 
 76 
it includes the desired UAA(s). In light of the facts in the preceding paragraph, it must be 
logical that RSs have mechanisms by which they distinguish correct tRNAs and amino 
acids from incorrect tRNAs and amino acids, ensuring that they aminoacylate only their 
intended tRNAs with the correct amino acid. As has been demonstrated previously by a 
number of groups, RSs recognize sequences and structures of tRNA molecules (2-4) as 
well as structures and functional groups of amino acids (5, 6). Therefore, RSs can be 
engineered to recognize mutant tRNAs and UAAs and thus can supplement the genetic 
code of cells or organisms to which they are added. The sequence and structural motifs 
by which RSs recognize correct tRNAs will be discussed in detail in the following section. 
tRNA Identity Determinants 
The genetic code is enforced by RS discrimination of correct tRNAs and amino 
acids, and correct tRNAs bear anticodons complementary to the codon by which their 
cognate amino acid is represented. Therefore the anticodon is an obvious candidate for 
a tRNA identity determinant. The first experimental evidence for the role of the 
anticodon in tRNA identity was presented in 1964 when chemical modification of the 
anticodon region of yeast tRNA abolished aminoacylation (7). This region has since been 
confirmed as a strong identity determinant for most tRNAs, but it is not the only one (8). 
Since amino acids are covalently attached to the 3’ terminal CCA on tRNA molecules, the 
nucleotides in that region were also strong candidates for identity determinants as they 
must physically interact in some way with the RS in order for the proper amino acid to 
be attached. In the 1970s, several groups used a number of experimental techniques to 
demonstrate that nucleotides in the tRNA acceptor stem region (See Figure 4.3 for 
acceptor stem location) do play a role in tRNA recognition by RSs and therefore can be 
classified as identity determinants (9-11). 
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Despite the fact that anticodon 
mutations can exert some effect on tRNA 
identity, they are not the most potent 
determinants of tRNA identity (5, 12). 
Instead, the nucleotides in the acceptor 
stem are stronger identity determinants 
as compared to those of the anticodon 
(13). Incidentally, this fact is 
instrumental in making UAA 
incorporation systems possible, because 
site-specific UAA incorporation requires the use of anticodon mutated tRNAs. If the 
anticodon were a very strong determinant of tRNA identity, this would present a 
problem. Himeno and colleagues used a series of tRNA mutants containing changes to 
the anticodon, the acceptor stem, and the variable loop of Escherichia coli (E. coli) 
tRNAser to determine which changes would allow charging of tRNAser by a tyrosyl tRNA-
synthetase (5). They found, as previously, that the anticodon did play a role in 
recognition, but for this particular tRNA-RS pair, other nucleotides were far stronger 
determinants of identity than the anticodon. For clarity’s sake it should be noted that 
tRNAs are numbered from 5’ to 3’. So if a tRNA has a nucleotide G3, that is the third 
nucleotide from the 5’ end, and it is a guanosine. Himeno and colleagues reported a 
strong effect on identity stemming from the so called discriminator base, located at 
position 73, directly 5’ of the terminal CCA (5). Anticodon mutation did not allow 
acylation of mutant tRNA by a tyrosyl RS, but anticodon mutation combined with 
Figure 4.3: tRNA secondary structure 
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discriminator base mutation and the addition of a tRNAser sequence in the variable loop 
of the mutant tRNA did allow charging of the mutant tRNAser by a tyrosyl-RS (5). 
Further corroborating the idea that acceptor stem nucleotides are strong 
determinants of tRNA identity, the Schimmel group has done a variety of experiments 
using RNA fragments to demonstrate that acceptor stem nucleotides alone can allow 
aminoacylation of RNA molecules (14-18). Perhaps the most important implication of 
this work is the idea that, without the effect of the anticodon, aminoacylation can be 
achieved by manipulation just the acceptor stem nucleotides. While there are effects 
from other nucleotides, like the previously mentioned instance in which the variable 
loop nucleotides played a role in tRNA identity, it is possible to create RNA or tRNA 
molecules which are easily usable substrates for RS aminoacylation by manipulation of 
only the acceptor stem nucleotides. This allows mutant amber suppressor tRNAs to be 
tailored to the specificity either of a canonical amino acid or UAA by choosing 
appropriate acceptor stem sequences.  
Since the project detailed in this dissertation is specifically designed for use in 
mammalian cells, the tRNA and RS used should be non-reactive with mammalian tRNAs 
and RSs. Therefore, it is important to know the specific identifiers commonly found in 
mammalian/eukaryotic tRNAs versus prokaryotic tRNAs. As mentioned in Chapter Two, 
Wakasugi et al demonstrated that, much like the tRNAser and tRNAala mentioned in the 
preceding paragraphs, the acceptor stem nucleotides are powerful identity 
determinants in human tRNAs (19). E. coli tRNAtyr (tRNAectyr) has acceptor stem 
nucleotides G1:C72, while human tRNAtyr (tRNAhstyr) has acceptor stem nucleotides 
C1:G72 (19). Methanocaldococcus jannaschii (M. jannaschii) has the same 1:72 base pair 
as tRNAhstyr. In both human and M. jannaschii based experiments, mutations which 
switched the identity of the 1:72 base pair were able to abolish aminoacylation by 
 79 
wildtype enzymes (19, 20). It is this experimental evidence on which the orthogonality 
of tRNA used in the UAA incorporation presented in this dissertation is based.  
OVERALL EXPERIMENTAL DESIGN 
The experiments detailed in this chapter pertain only to the initial design and 
creation of the system, while Chapter Five and Chapter Six cover its implementation in 
P19 embryonal carcinoma cells. The design, optimization and implementation of a UAA 
incorporation system for use in mammalian cells is a multifaceted project. As such, it 
was broken down into several parts, some of which were completed in parallel. Those 
parts are described briefly below, and the experimental details of each will follow. 
1. Reporter Plasmid Optimization 
Since previous experiments using HEK293T cells and the TAG reporter 
protein received from the Schultz group indicated background expression 
of green fluorescent protein in the absence of either tRNA or RS 
constructs, it was necessary to create a new reporter plasmid. 
2. tRNA and RS Creation and Optimization 
Since previously evolved RSs with specificities for a number of useful 
UAAs are based upon the M. jannaschii tRNA/RS pair, modifications were 
made to that pair to transfer it to mammalian cells. The tRNA was made 
orthogonal to mammalian systems and given a new promoter to increase 
tRNA levels, and the CP1 region of the M. jannaschii RSTyr was replaced 
with that of E. coli. The D286R mutation was also introduced to increase 
aminoacylation efficiency of the amber suppressor tRNA. 
3. tRNA Acceptor Stem Optimization 
Since nucleotides beyond simply the discriminator base and the 1:72 pair 
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have been implicated in RS recognition of various other tRNAs from 
multiple species, a tRNA database was used to find an acceptor stem that 
would be completely orthogonal to the human system. This was done to 
eliminate the background amber suppression seen in previous versions of 
this system by making the amber suppressor tRNA completely orthogonal 
to the mammalian system. 
4. Condensation of UAA incorporation System to a 2-Plasmid System 
Since transfection efficiencies in P19s are expected to be lower than 
those achieved in other cell lines, it could be helpful to put the necessary 
DNA constructs into two bidirectional plasmids instead of three one-
directional plasmids. To that end, the genes encoding the reporter 
protein, the tRNA, and the RS were transferred to bidirectional plasmids. 
Completion of these four goals will result in successful stop codon suppression, 
which is not the same as UAA incorporation. However, stop codon suppression in this 
case is the first step toward UAA incorporation, and indicates feasibility of UAA 
incorporation. Chapter Six will discuss the details involved in progressing from stop 
codon suppression to actual incorporation of UAAs. 
MATERIALS AND METHODS 
New Reporter Protein Plasmid Construction 
The plasmid p-EGFPN1 was purchased from Clontech. The 40th codon was 
mutated from TAC to TAG using site-directed mutagenesis (SDM). Forward and reverse 
primers were designed using Stratagene’s online primer design program, and sequences 
are below. All DNA sequences are listed in the normal convention of 5’-3’. 
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Forward Primer: GCGAGGGCGAGGGCGATTAGACCTACGGCAAGC 
Reverse Primer: GCTTGCCGTAGGTCTAATCGCCCTCGCCCTCGC 
The QuickChange II Site-Directed Mutagenesis Kit was purchased from 
Stratagene (Stratagene, Agilent Technologies, Inc., Santa Clara, CA), and SDM was 
completed according to the provided protocol. Plasmids were sequenced by the 
University of Texas at Austin ICMB DNA Sequencing Facility. The new plasmid was 
termed 40TAG-peGFPN1. 
Routine Cell Culture 
HEK293T cells were purchased from Invitrogen (Carlsbad, CA). Complete 
HEK293T media was composed of high glucose DMEM with 4500 mg/L of sodium 
bicarbonate and L-glutamine (Sigma-Aldrich, St. Louis, MO) supplemented with 10% 
(v/v) fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and 1X 
nonessential amino acids (Sigma-Aldrich, St. Louis, MO). Cells were maintained in a 
humidified incubator at 37° Celsius with 5% CO2 atmosphere. Cells were passaged every 
2-3 days at ratios between 1:10 and 1:20. Passaging was accomplished by washing cells 
with phosphate buffered saline (PBS) (Sigma-Aldrich, St. Louis, MO), treating with 0.5% 
trypsin (Sigma-Aldrich, St. Louis, MO) for 2-5 minutes, and harvesting via centrifugation. 
In between passaging, fresh media was added to cells every 24 hours. 
Testing of New Reporter Protein Plasmid 
After sequencing confirmed successful creation of 40TAG-peGFPN1, it was tested 
by introduction to mammalian cells and fluorescence assisted cell sorting (FACS). 
HEK293T cells were grown in 6-well plates to between 70% and 90% confluency for each 
experiment. On the day of transfection, DNA for both 40TAG-peGFPN1 and the 
previously used TAG reporter protein encoding plasmid, Lital40TAG, was introduced to 
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HEK293T cells with FugeneHD (Roche, Switzerland). FugeneHD was used according to 
the manufacturer’s protocol using a 2:1 ratio of µL FugeneHD to µg DNA. Complexes 
were formed in Opti-Mem (Gibco, Invitrogen, Carlsbad, CA) and added dropwise to 
wells. 
24 hours after transfection, cells were imaged using a Nikon Eclipse TE2000-S 
microscope with a FITC HyQ filter (Chroma, Rockingham, VT). Cells were then harvested 
for FACS. Briefly, the passaging protocol was followed up to the point of centrifugation. 
After centrifugation, cells were washed once in PBS and recentrifuged. PBS supernatant 
was aspirated, and cells were resuspended in 4% paraformaldehyde in PBS (USB Corp. 
Cleveland, OH). Cells were incubated in paraformaldehyde for 15 minutes, then re-
centrifuged. Paraformaldehyde was aspirated, and cells were resuspeded in PBS then 
subjected to FACS. FACS was accomplished using a BD FacsCalibur, and data analysis was 
done using Cyflogic. For all FACS experiments, dead cells were excluded using forward 
and side scatter. GFP gating was done by designating the area of the GFP histogram 
occupied by untransfected cells as “GFP Negative,” and all cells exhibiting higher 
fluorescence than untransfected cells were classified as “GFP Positive.” 
Creation of Orthogonal tRNA from M. jannaschii tRNA 
All restriction enzymes were purchased from New England Biolabs (Ipswich, MA), 
and all oligonucleotides were purchased from Sigma-Aldrich (St. Louis, MO) unless 
otherwise indicated. The orthogonal tRNA for M. jannaschii was created by ordering 
oligonucleotides which included all the desired mutations, including the G1:C72 base 
pair and the amber anticodon. Those primers are shown below. 
Forward: GAAGATCTCCGGCGGTAGTTCAGCCTGGTAGAACGGCGGACTCTAA 
  ATCCGCATGTCGCTGGTTCAAATCCGGCCCGCCCGAGACAAGTGCG 
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  GTTTTTTT 
Reverse: CCAATGCATTGGTTGCCCGCTCGAGTAGAAAAAAACCGCACTTGTC 
  TCCGGCGGGCCGGATTTGAACCAGCGACATGCGGATTTAGAGTCCG 
  CCGTTCTA 
The above oligonucleotides were boiled and allowed to come to room 
temperature unaided. They were then extended using the Klenow fragment of E. coli 
DNA polymerase (New England Biolabs, Ipswich, MA). This DNA fragment was double-
digested with BglII and PstI and cleaned up using a Qiagen PCR Cleanup Kit (Valencia, 
CA). The plasmid pTRE-Tight was purchased from Clontech (Mountainview, CA), double 
digested with BglII and PstI then treated with calf-intestinal-phosphatase (CIP) (New 
England Biolabs, Ipswich, MA). The resultant fragments were separated on a 1% agarose 
gel. The larger fragment was purified out of the gel using a Qiagen Gel Extraction Kit 
(Valencia, CA). The annealed and digested tRNA DNA was then ligated into the pTRE-
Tight fragment using T4 DNA Ligase to afford the plasmid pTRE-Tight-MJtRNATyr. 
Since pTRE-Tight-MJtRNATyr has no promoter for tRNA synthesis, the human H1 
promoter was inserted 5’ of the tRNA. The human H1 promoter was constructed in a 
similar manner to the tRNA DNA fragment. The forward and reverse primers for the 
human H1 promoter are below. 
Forward: CAACCCGCTCCAAGGAATCGCGGGCCCAGTGTCACTAGGCGGGAAC 
  ACCCAGCGCGCGTGCGCCCTGGCAGGAAGATGGCTGTGAGGGACAG 
  GGGAGTGGCGCCCTGCAA 
Reverse: GAACTTATAAGATTCCCAAATCCAAAGACATTTCACGTTTATGGTGA 
  TTTCCCAGAACACATAGCGACATGCAAATATTGCAGGGCGCCACTC 
  CCCTGTCCCTCACAGCC 
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The above oligonucleotides were annealed as explained for the tRNA DNA 
above. The fragment was then amplified by polymerase chain reaction (PCR) using the 
primers below: 
Forward: GGAATTCCAATTCGAACGCTGACGTCATCAACCCGCTCCAAGGAA 
  TC 
Reverse: GAAGATCTGTGGTCTCATACAGAACTTATAAGATTCCCA 
The resultant DNA fragment was digested with KpnI and BglII while pTRE-Tight-
MJtRNATyr was simultaneously digested with the same enzymes. Digested pTRE-Tight-
MJtRNATyr was treated with CIP, and then subjected to agarose gel electrophoresis, as 
mentioned above. The larger fragment was then gel purified, and the human H1 
promoter fragment was purified as well, both as previously mentioned for construction 
of the original pTRE-Tight-MJtRNATyr. The human H1 promoter fragment was ligated 
into the purified backbone of pTRE-Tight-MJtRNATyr to afford the plasmid 312tRNA 
which includes the human H1 promoter upstream of the newly orthogonal amber 
suppressor tRNA based upon M. jannaschii tRNAtyr. 
The same process was used to create a plasmid encoding the wildtype M. 
jannaschii tRNAtyr, which was used in multiple experiments as a pseudo positive control 
as well as an earmark of the level at which tRNA is produced in mammalian cells. This 
was done using oligonucleotides encoding the wildtype acceptor stem and the amber 
anticodon and afforded the plasmid wtMJtRNA. The correct sequence of this plasmid 
was confirmed by sequencing (UT ICMB DNA Sequencing Facility, TX). 
Orthogonality Testing of tRNA Constructs 
HEK293T cells were grown to 70-80% confluency in 6-well plates (Corning, 
Lowell, MA) and then cotransfected 40TAG-peGFPN1 and each of the various tRNA 
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Figure 4.4: Schematic of chimeric RS construction depicting 
orthogonal RS with N and C termini from M. 
jannaschii and CP1 region from E. coli 
constructs mentioned previously (i.e. each tested tRNA was transfected along with 
40TAG-peGFPN1, not with other tRNAs). FugeneHD was used for transfection, and 
complexes were formed in Opti-Mem using a ratio of 2 µL FugeneHD to 1 µg DNA. 
Media was changed every 24 hours after transfection. Cells were imaged using a Nikon 
Eclipse TE2000-S microscope with a FITC HyQ filter (Chroma, Rockingham, VT) every 24 
hours after transfection. At 48 hours post-transfection, cells were harvested for FACS. 
Briefly, the passaging protocol was followed up to the point of centrifugation. After 
centrifugation, cells were washed once in PBS and recentrifuged. PBS supernatant was 
aspirated, and cells were resuspended in 4% paraformaldehyde in PBS (USB Corp. 
Cleveland, OH). Cells were incubated in paraformaldehyde for 15 minutes, then re-
centrifuged. Paraformaldehyde was aspirated, and cells were resuspeded in PBS then 
subjected to FACS. FACS was accomplished using a BD FacsCalibur, and data analysis was 
done using Cyflogic. 
Creation of RS for Charging Orthogonal tRNA with Tyrosine 
The wildtype M. jannaschii tyrosyl-tRNA synthetase (RSmjwt) was created by 
introducing the D286R mutation mentioned previously and swapping the E. coli CP1 
region for that of M. jannaschii (21) to afford the EME chimeric protein shown in . 
Briefly, the gene for 
RSmjwt was amplified via 
PCR, digested, and 
ligated into pEF6-V5-
TOPO (Invitrogen, 
Carlsbad, CA) using the 
 86 
manufacturer’s protocol. 






The CP1 region of E. coli tyrosyl-tRNA synthetase was amplified from an in-house 
plasmid using the following primers: 
Forward: ATGGAAGTGAATTCCAGTG GTTC GGCAATATGAATGT 
Reverse: TGCATTATTGGATAGATAACTTCAGTGAACGAAATCCCCT 
1 ug of each PCR product (N-terminus of RSmjwt , C-terminus of RSmjwt, and CP1 
region of E. coli tyrosyl-tRNA synthetase) was combined, denatured for 15 minutes at 
85° Celsius, and elongated with the Klenow fragment of E. coli DNA polymerase (New 
England Biolabs, Ipswich, MA). The fragment was then amplified using the N-Forward 
and C-Reverse primers mentioned on the preceding page. The resultant fragment was 
then digested, as was pEF6/V5, with HindIII and EcoRI. The digestion products were 
purified and cleaned up as mentioned in the preceding sections, and they were then 
ligated to afford the plasmid 309RS. This plasmid encodes the chimeric MEM protein 
shown in Figure 4.4. The correct sequence of this plasmid was confirmed by DNA 
sequencing (UT ICMB DNA Sequencing Facility, TX). 
Amber Stop Codon Suppression Assay 
HEK293T cells were grown to 70%-80% confluency as previously described. They 
were transfected with the elements of the UAA incorporation system described in the 
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preceding pages. The various combinations of constructs employed in those 









Transfections were carried out as previously described with FugeneHD. 
Complexes were made and added to cells according to the manufacturer’s instructions 
using Opti-Mem as the diluents and a ratio of 2 µL FugeneHD to 1 µg DNA. Media was 
changed every 24 hours after transfection, and cells were imaged immediately prior to 
media changes using a Nikon Eclipse TE2000-S microscope with a FITC HyQ filter 
(Chroma, Rockingham, VT). After 72 hours, cells were harvested for FACS. As described 
previously, the passaging protocol was followed up to the point of centrifugation. After 
centrifugation, cells were washed once in PBS and recentrifuged. PBS supernatant was 
aspirated, and cells were resuspended in 4% paraformaldehyde in PBS (USB Corp. 
Cleveland, OH). Cells were incubated in paraformaldehyde for 15 minutes, then re-
centrifuged. Paraformaldehyde was aspirated, and cells were resuspeded in PBS then 
subjected to FACS. FACS was accomplished using a BD FacsCalibur, and data analysis was 
done using Cyflogic.  
 
Table 4.1: DNA included in amber stop codon suppression 
assay conditions. The left hand column is the 
name of each condition, while the top row lists 
the DNA used. ‘+’ means the DNA was included, 
‘-‘ means the DNA was not included. 
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Acceptor Stem Optimization and Creation of Super Orthogonal tRNA 
To find an acceptor stem completely unlike any human tRNA, the tRNAdb 2009 
was used (22). The acceptor stem sequences for every human tRNA were compiled, and 
then a search was done using the database to find an acceptor stem sequence for a 
tyrosyl tRNA with 0 sequence homology to any human tRNA. Only one tRNA was found 
which fit this description, belonging to the malaria causing parasite Plasmodium 
falciparum (P. falciparum). To test the orthogonality of this acceptor stem, 
oligonucleotides encoding an amber suppressor form of the P. falciparum tRNA were 





The forward and reverse oligonucleotides were combined in equimolar 
quantities, boiled, and allowed to come to room temperature unaided. They were then 
digested with BglII and PstI, as was the plasmid 312tRNA. The digested 312tRNA was 
separated via agarose gel electrophoresis and gel purified. The digested and purified P. 
falciparum tRNA fragment was then ligated into the 312tRNA backbone to afford the 
plasmid PfalctRNA. The correct sequence of this plasmid was confirmed by sequencing 
(UT ICMB DNA Sequencing Facility, TX). 
Creation of 2-Plasmid UAA incorporation System 
The plasmid pBi-CMV4 was purchased from Clontech (Mountainview, CA). The 





The resultant PCR product and the plasmid pBi-CMV4 were separately digested 
with EcoRV and HindIII. pBiCMV4 was also treated with CIP. Both double digest products 
(pBiCMV4 and PCR product) were separated via agarose gel electrophoresis as 
previously described. They were then gel purified using a Qiagen Gel Purification Kit 
(Valencia, CA). The PCR product was then ligated into pBiCMV4 using T4 DNA Ligase 
(Fermentas Inc., Thermo Scientific, Glen Burnie, MD) to afford the plasmid pBi-309. 
The DNA encoding eGFP with an amber stop codon at the 40th position was 
amplified by PCR out of 40TAG-peGFPN1 using the primers below. 
Forward: TGGAGAATTCTGCAGTCGACGGT  
Reverse: CCTCTAGAGTCGCGGCCGCTTTACTTGTACAGCTCGT 
The resultant PCR product, along with pBi-309, was digested with EcoRI and 
XbaI. pBi-309 was then treated with CIP to prevent self ligation. Both digestions were 
then separated by agarose gel electrophoresis, and the appropriate bands were 
removed then cleaned up as described above. The 40TAG-GFP segment was ligated into 
the pBi-309 backbone using T4 DNA Ligase (Fermentas Inc., Thermo Scientific, Glen 
Burnie, MD) to afford the plasmid 40TAG-bi-309. The correct sequence of this plasmid 
was confirmed by sequencing (UT ICMB DNA Sequencing Facility, TX). 
In order to remove both the human H1 promoter as well as the previously 
designed orthogonal tRNA, the plasmid 312tRNA was double digested with BglII and 
XhoI, as was pBiCMV4. The digested pBiCMV4 was treated with CIP, and then separated 
using agarose gel electrophoresis, as was the digested 312tRNA plasmid. The 
appropriate bands were cut out of each lane and purified as previously described. The 
312tRNA insert was ligated into the pBiCMV4 backbone using T4 DNA Ligase (Fermentas 
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Inc., Thermo Scientific, Glen Burnie, MD) to afford the plasmid pBi-312. Since pBiCMV4 
already has a gene in it for a variant of red fluorescent protein (RFP), this plasmid was 
created so that cells could monitored for GFP expression, indicative of stop codon 
suppression, and for RFP, indicative of transfection with the tRNA carrying plasmid. The 
correct sequence of this plasmid was confirmed by sequencing (UT ICMB DNA 
Sequencing Facility, TX). 
Testing of 2-Plasmid UAA Incorporation System 
The components of the two-plasmid incorporation system were tested in 
HEK293T cells. The cells were plated in 6-well plates and grown to 70%-80% confluency. 
They were transfected with the respective components of the 3-plasmid UAA 
incorporation system and the 2-plasmid UAA incorporation system using Fugene HD as 
previously described. Media was changed 24 hours after transfection and every 24 
hours after that. Cells were imaged using a Nikon Eclipse TE2000-S microscope with a 
FITC HyQ filter (Chroma, Rockingham, VT) every 24 hours as well. Depending upon the 
Table 4.2: DNA included in comparison of 3-plasmid and 2-plasmid UAA 
incorporation systems. The left hand column is the name of each 
condition, while the top row lists the DNA used. ‘+’ means the DNA 
was included, ‘-‘ means the DNA was not included. 
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experiment, cells were harvested for FACS at either 48 hours or 72 hours post-
transfection. FACS harvesting was done as previously described on page 84. The DNA 
constructs used in each condition are shown in Table 4.2. 
RESULTS AND DISCUSSION 
Reporter Protein Plasmid Optimization 
Since the plasmid encoding the reporter protein used by another group 
consistently yielded background expression of reporter protein, a new one was created 
based upon the peGFP-N1 plasmid from Clontech. This plasmid was optimized for 
expression in mammalian cells and had a strong constitutive promoter. The promoter on 
the previous plasmid, Lital40TAG, was unknown, and sequencing attempts consistently 
failed. Thus, SDM was used to create the new fluorescent reporter protein encoding 
plasmid, 40TAG-peGFPN1, which is the same as the original plasmid except for a 
mutation from a tyrosine codon to an amber stop codon at the 40th position. In order to 
confirm that the new reporter protein encoding plasmid did actually yield lower 
Figure 4.5: Fluorescent images demonstrating decreased background expression of 
40TAG GFP from new plasmid 40TAG-peGFPN1 as compared to Lital40TAG. 
Unmodified images were taken 48 hours after transfection with gain set to 1 
and 1 second exposure time. Contrast Increased images (bottom row) are the 
original images with contrast increased 72% using Adobe Photoshop. 
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background expression than the earlier version, HEK293T cells were transfected with 
each plasmid and expression of GFP was assessed via fluorescence microscopy as well as 
FACS. In order to facilitate visual appreciation of the background expression of reporter 
protein in the Lital40TAG condition, the original images were modified by increasing 
contrast by 72% using Adobe Photoshop. As evidenced by Figure 4.5, 40TAG-peGFPN1 
produces less background expression of TAG-GFP protein than its predecessor 
Lital40TAG. Though this difference is difficult to see, the contrast enhanced version of 
the Lital40TAG image clearly shows four fluorescent cells. Neither the negative control, 
nor the 40TAG-peGFPN1 condition exhibits this same level of fluorescence.  
To further confirm that 40TAG-peGFPN1 produces less background than 
Lital40TAG, cells were harvested and subjected to FACS using a BD FacsCalibur. As 
previously mentioned, dead cells were excluded using forward and side scatter, and the 
category of GFP positive was assigned to cells exhibiting higher fluorescence than those 
in the No DNA negative control condition. Figure 4.6 shows the FACS results, confirming 
the information presented in Figure 4.5, that 40TAG-peGFPN1 produces less background 
expression of viable GFP protein. Though the mechanism behind this background 
expression from the Lital40TAG plasmid, my colleagues and I have speculated that there 
may be more than one version of TAG-GFP gene in that plasmid, which may explain the 
consistent sequencing failures. If the second version of the TAG GFP gene had the 
amber stop codon in a place downstream of the UV core of GFP, it may be possible for 
some percentage of that protein to fold well enough to exhibit fluorescence. Regardless 
of the mechanism behind the background expression found in Lital40TAG transfected 
cells, the new plasmid 40TAG-peGFPN1 clearly produces less background and thus was 



















Testing of Orthogonal tRNA 
The plasmids encoding both the newly created orthogonal tRNA (312tRNA 
plasmid) as well as the non-orthogonal tRNA (wtMJtRNA plasmid) were transfected into 
HEK293T cells along with 40TAG-peGFPN1. If full length GFP were produced in either 
condition, it would indicate that the tRNA encoded within the transfected plasmid was 
not orthogonal. Therefore, if the tRNA encoded by the plasmid 312tRNA is as orthogonal 
as intended, it should not produce full length GFP. Since the tRNA encoded by the 
plasmid wtMJtRNA is not intended to be orthogonal, it was used as a measure of tRNA 
Figure 4.6: HEK293T cells exhibiting GFP fluorescence as determined by FACS. The new 
plasmid 40TAG-peGFPN1 exhibits 80% less background fluorescence than 
Lital40TAG and less than 50% more than the negative control. 
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transcription levels as well as the capacity of HEK293T cells to produce functional 
exogenous tRNA from plasmid DNA. Both Figure 4.7 and Figure 4. 8 demonstrate 
successful expression of amber suppressor tRNA (wtMJtRNA) and orthogonality of the 






















Figure 4.7: Fluorescent images demonstrating orthogonality of 312tRNA as well as tRNA 
expression (wtMJtRNA) in HEK293T cells. Images were taken 48 hours after 
transfection with gain set to 1 and 1 second exposure time 
Figure 4. 8 : HEK293T cells exhibiting GFP fluorescence as a result of amber 
suppression as determined by FACS. 
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Testing of Complete UAA Incorporation System 
In order to confirm the intended functionality of the complete UAA 
incorporation system, including the products of plasmids 40TAG-peGFPN1, 312tRNA, 
and 309RS, the components of the system were transfected into HEK293T cells as 
detailed in Table 4.1. Images taken 48 hours after transfection are shown in Figure 4.7 
below. 
 
Since the differences between the tRNA control condition and the Suppress 
condition were subtle in the original pictures, the levels of each image were changed 
from 0-255 to 0-110 using Adobe Photoshop. This technique brings out the green cells 
more clearly than the original images. In the Levels Altered row, the Suppress Condition 
clearly has about twice the percentage of fluorescent cells as the tRNA condition, which 
Figure 4.9: Fluorescent images demonstrating functionality of UAA Incorporation System 
in HEK293T cells transfected as described in Table 4.1. Unmodified images 
were taken 48 hours after transfection with gain set to 1 and 1 second 
exposure time. Levels Altered images (bottom row) are the original images 
with the levels changed from 0-255 to 0-110 using Adobe Photoshop. The 
Levels Altered version of the Suppress condition clearly demonstrates are 
higher percentage of fluorescent cells than the Levels Altered version of the 
tRNA control condition. 
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indicates a number of things. First, the engineered chimeric synthetase encoded by the 
309RS plasmid appears to successfully charge the tRNA encoded by the 312tRNA 
plasmid. This is indicated by the increased percentage of fluorescent cells in the 
Suppress condition versus the tRNA condition. Second, the tRNA is not completely 
orthogonal. Though this was previously established by the tRNA orthogonality assays, it 
serves to further solidify the idea that creating an orthogonal tRNA for use in 
mammalian cells may be more difficult than previously anticipated. This was just one of 
the many reasons why it was prudent to use the tRNAdb 2009 and find an acceptor 
stem completely different than any human acceptor stem, as discussed in the following 
section.  
Creation of Super Orthogonal tRNA 
Since many groups have previously established that nucleotides in the acceptor 
stem other than the 1:72 base pair and discriminator nucleotide often play a role in 
identity determination (3, 4, 6, 9, 23, 24), we attempted to make a super orthogonal 
tRNA by finding an acceptor stem sequence with 0% homology with any human tRNA 
acceptor stem. Since the pilot test of this tRNA occurred in human cells, it was to be a 
proof of concept that screening for acceptor stem homology within tRNAs native to the 
host cell can improve orthogonality. In the event that this technique worked, it could 
then be applied to other systems. Thus, by comparing acceptor stem sequences of all 
known human tRNAs to acceptor stem sequences from all known tyrosyl-tRNAs from 
any organism, a tRNA from the parasite Plasmodium falciparum was found which had a 
completely different acceptor stem sequence than any human tRNA. Oligonucleotides 
were ordered for an amber suppressor tRNA based upon this sequence, and its DNA was 
cloned into the previously developed expression cassette (see page 82). To test the 
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orthogonality of this tRNA, it was cotransfected into HEK293T cells along with 40TAG-
peGFPN1. Thus, orthogonality could be assessed by fluorescence as with previous 
orthogonality assays. For comparison, cells were also cotransfected with the previously 
created 312tRNA and 40TAG-peGFPN1. Though once again the fluorescent images do 
not make the distinction between conditions overt, there are subtle differences as 
evidenced by Figure 4.8.  
 
Interestingly, the difference between the P. falciparum condition and the 
312tRNA condition is difficult to discern. However it is clear that neither the P. 
falciparum condition nor the 312tRNA condition is entirely orthogonal. From this 
information alone, one cannot determine conclusively whether or not the P. falciparum 
Figure 4.10: Comparison of P. falciparum amber suppressor tRNA and tRNA produced 
by 312tRNA plasmid. Higher fluorescence in the P. falciparum condition 
indicates that it is less orthogonal than the tRNA encoded by the 312tRNA 
plasmid. Images were taken 48 hours after transfection, each with gain set 
to 1 and a 1 second exposure time. 
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tRNA is a suitable candidate for further investigation or optimization, but the FACS data 
aid tremendously in this endeavor. 
As shown in Figure 4.9, the pfalctRNA does actually produce less fluorescence 
than the 312tRNA, though both of them produce suboptimal amounts of amber 
suppression in the absence of synthetases engineered to charge them with either amino 
acids or UAAs. In these experiments, the voltage on the blue laser used to excite GFP 
fluorescence was turned up in order to highlight the differences between the two tRNAs 
tested and the 40TAG-peGFPN1 negative control. If compared only to each other, the 
pfalctRNA seems to exhibit about 25% less fluorescence than the 312tRNA, but that 
Figure 4.11: HEK293T cells exhibiting GFP fluorescence as a result of amber suppression, 
determined by FACS.  
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comparison is not the most faithful metric for comparing the two tRNAs. Instead, they 
should each be compared to the 40TAG-peGFPN1 condition. When that comparison is 
done, the pfalctRNA produces about twice the level of fluorescence as the reporter 
plasmid alone, and the 312tRNA produces almost three times the fluorescence of the 
reporter plasmid alone. If this information alone was used to judge the usefulness of the 
pfalctRNA, then it would indicate that the pfalctRNA is a better candidate for further 
development than the 312tRNA. 
Unfortunately, orthogonality is not the only consideration in this project. The M. 
jannaschii system was initially chosen because multiple synthetases have already been 
developed and in fact already exist in the lab for the incorporation of multiple UAAs. The 
process involved in developing new synthetases is anything but simple, but would be 
worthwhile if a completely orthogonal tRNA could be found. In that case, development 
of a new system using that tRNA as a jumping off point would make sense both 
scientifically as well as financially. However, since the P. falciparum tRNA did not 
represent even a 50% decrease in background amber suppression, it seemed an unwise 
decision to pursue it any further. Since it did decrease the background to a degree, we 
decided to test it with a number of in-house synthetases to see if perhaps it would fit 
with one of them. If so, then it would be a useful addition to the project, and if not, the 
project could move forward with the suboptimally orthogonal 312tRNA. 
One important piece of information indicated by the P. falciparum tRNA is that 
orthogonality is more complex than we currently understand. Though the P. falciparum 
tRNA contains an acceptor stem which is completely foreign to the mammalian system, 
there is some endogenous synthetase, and perhaps multiple synthetases, which 
recognize this foreign acceptor stem and successfully charge it with an amino acid. 
Perhaps the most incredible part of this phenomenon is the fact that, taken at face 
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value, it may lead one to believe that endogenous RSs are simply sloppy and capable of 
making mistakes. Once again, that would be a hasty and incorrect conclusion from this 
information. First of all, we have no metric with which to gauge the amount of tRNA 
produced by the 312tRNA or the pfalctRNA plasmids. It could be that these tRNAs are 
produced in quantities much higher than endogenous tRNAs, making the cells 
statistically more prone to RS recognition errors than they would be in a normal 
situation. Even if these tRNAs are produced in the same quantities or less than 
endogenous tRNAs, there is still little evidence to support the idea that endogenous RSs 
could be making recognition mistakes. This is simply due to the fact that, if they were, 
certainly they would be making those mistakes in the absence of exogenous tRNAs, and 
those mistakes would be reflected in an inability to produce and then analyze the 
sequence of proteins expressed in mammalian cells. Since proteins are successfully 
expressed all the time in mammalian cells without frequently misincorporated amino 
acids, the reason for mischarging of the exogenous tRNAs in this project is very unlikely 
to be mistakes made by endogenous RSs. Thus, what we can conclude from this portion 
of the project is that tRNA identity elements are still poorly understood, making it 
difficult to create any completely orthogonal UAA incorporation system. Keeping that in 
mind, the 312tRNA, which exhibits about 33% more background than the pfalctRNA, is 
an acceptably orthogonal solution to a poorly understood problem. 
Testing of 2-plasmid UAA Incorporation System 
The UAA incorporation system initially developed on pages 84 and 85 of this 
Chapter is housed in three separate plasmids. In order to decrease the burden of 
optimization on stem cell transfection (described in Chapter Three), this system was 
condensed into two bidirectional plasmids. This two plasmid UAA incorporation system 
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was then tested in HEK293T cells to assess its functionality as compared to the original 
three plasmid UAA incorporation system. HEK293T cells were transfected with either 
the two-plasmid or the three-plasmid system and assessed via fluorescence microscopy 
and FACS. Figure 4.10 shows the images of cells transfected with the different UAA 
incorporation systems 72 hours post-transfection. From this figure, it is clear that the 
two-plasmid system performs poorly in comparison to the three-plasmid system, which 
is somewhat surprising. Unfortunately, this conclusion is further corroborated by the 
FACS data in Figure 4.10, which shows again that the two-plasmid system achieves a 
lower level of amber stop codon suppression than the three-plasmid system. On one 
hand, the two-plasmid system exhibits little to no background, but it also exhibits little 
to no suppression. Thus, in choosing which system to move forward with, the logical 
conclusion is to choose the three-plasmid system, though a more ideal situation would 
be to improve the performance of the two-plasmid system. 
In order to improve the performance of the two-plasmid system, it is first 
necessary to identify the possible reasons for its surprisingly bad performance. Though 
time was insufficient to investigate these reasons, there are a few possible culprits that 
may be targets for future improvements of this system. The original 40TAG-peGFPN1 
plasmid contains a cytomegalovirus (CMV) promoter, but the pBi-CMV4 plasmid which 
houses the two-plasmid system has a minimal CMV promoter. It is possible that the 
minimal CMV promoter simply does not produce enough protein in HEK293T cells to be 
useful for a UAA incorporation system. Furthermore, the 312tRNA plasmid has tet-
responsive element (TRE) upstream of the human H1 promoter. While the human H1 
promoter was transferred to the two-plasmid system, no tests were ever done to assess 
the influence of the TRE based promoter on tRNA transcription levels. Thus, it is difficult 
to say whether or not tRNA is being produced by the two-plasmid system. With any 
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tRNA tested thus far, there has been some level of recognition and charging of that 
tRNA by endogenous synthetases. Since the two-plasmid system does not appear to 
exhibit any background at all, it is likely that it is not producing enough tRNA, if it is 
producing any at all. 
If the two-plasmid version of the UAA system had excluded the H1 promoter, 
depending only on the CMV promoter to drive tRNA transcription, it would seem likely 
that very little if any tRNA was being produced. Boden et al compared the ability of the 
CMV promoter, the human H1 promoter, and several others to produce RNA in HEK293T 
cells (25). They found that the CMV promoter was a poor choice for transcription of 
RNA, and in fact its ability to produce silencing RNA was almost identical to a negative 
control (25). Thus, if the two-plasmid system had used only a CMV promoter to drive 
tRNA transcription, that would have constituted a very serious design flaw and easily 
explained the poor performance of the system. However, as with many of the tRNA 
producing plasmids previously developed in our lab, this one left the original protein 
promoter intact, and inserted the tRNA promoter downstream of it. Thus, it is difficult 
to ascertain exactly why the two-plasmid system did not function as highly as the three-
plasmid system. Without further investigation, a definitive conclusion is impossible to 
make. However, removing the CMV promoter from the two-plasmid system and testing 
a variety of promoters, including full-length CMV promoters for 40TAG-GFP and 309RS 




Figure 4.12: Comparison of two-plasmid versus three-plasmid UAA Incorporation System in 
HEK 293T cells indicating decreased performance of the two-plasmid system 
as compared to the three plasmid system. (A) GFP fluorescence at 72 hours 
post-transfection. Images captured with gain of 1 and 1 second exposure. (B) 
GFP positive cells as determined by FACS. 
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Amber Stop Codon Suppression in P19 Embryonal Carcinoma Cells 
INTRODUCTION 
Chapter Four described the creation of an unnatural amino acid (UAA) 
incorporation system for use in mammalian cells by CP1 swap methodology, and 
Chapter Three described the development of a transfection protocol capable of 
efficiently transfecting P19 embryonal carcinoma cells (P19s). In this chapter, the use of 
the UAA incorporation system in P19 embryonal carcinoma cells using the previously 
developed transfection method will be described. First, some relevant background will 
be reviewed and expanded upon, and then our achievement of amber stop codon 
suppression in P19s will be described in detail. 
Overall Experimental Design 
Since suppression in HEK293T cells was successful, we chose to directly transfer 
the components of the UAA incorporation system to P19s. Both the original 
electroporation method and the hybrid FugeneHD+electroporation method (see 
Chapter Three) were used, because work on many aspects of this project was completed 
in parallel. Since the suppression in HEK293T cells was not remarkably successful, it was 
uncertain whether or not the UAA incorporation system developed in Chapter Four 
would function in P19s. Undifferentiated cells are known to respond differently to 
various promoters than other cell lines, and in fact some are unresponsive to 
cytomegalovirus (CMV) based promoters prior to differentiation (1, 2). Thus, we held it 
as a possibility that the UAA incorporation system might not work in P19s. Further, we 
concede the fact that CP1 swap methodology does work in HEK293T cells (3), but that 
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does not mean that protein translational machinery and protein folding pathways are 
identical in HEK293T cells and P19s. This means that while UAA incorporation systems 
for use in regular, easily transfectable, non-differentiable mammalian cells lines can be 
created via CP1 swap methodology and simple tRNA engineering, again, this does not 
necessarily transfer perfectly to P19s. To that end, we reasoned that another, more 
robust (though less accessible), UAA incorporation system should be tested for 
successful amber stop codon suppression in mammalian cells. So we created the 
components for using a UAA incorporation system based upon the Escherichia coli (E. 
coli) tyrosyl-tRNA/aminoacyl-tRNA synthetase pair. Since this pair has been evolved to 
incorporate a number of UAAs in eukaryotic cells, it is possible that the active site and 
tRNA recognition elements of the synthetase will function at a higher level than those of 
the chimeric enzyme created in Chapter Four. Therefore, both the E. coli and 
Methanocaldococcus jannaschii (M. jannaschii) based UAA incorporation systems were 
introduced to P19s using the previously developed transfection methods. Success of 
either or both UAA incorporation systems in suppressing an amber stop codon would 
allow progression to incorporation of useful UAAs into proteins in P19s. 
 
 
MATERIALS AND METHODS 
Routine Cell Culture 
HEK293T cells were purchased from Invitrogen (Carlsbad, CA). Complete 
HEK293T media was composed of high glucose DMEM with 4500 mg/L of sodium 
bicarbonate and L-glutamine (Sigma-Aldrich, St. Louis, MO) supplemented with 10% 
(v/v) fetal bovine serum (FBS) (Atlanta Biologicals, Lawrenceville, GA) and 1X 
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nonessential amino acids (Sigma-Aldrich, St. Louis, MO). Cells were maintained in a 
humidified incubator at 37° Celsius with 5% CO2 atmosphere. Cells were passaged every 
2-3 days at ratios between 1:10 and 1:20. Passaging was accomplished by washing cells 
with phosphate buffered saline (PBS) (Sigma-Aldrich, St. Louis, MO), treating with 0.5% 
trypsin (Sigma-Aldrich, St. Louis, MO) for 2-5 minutes, and harvesting via centrifugation. 
In between passaging, fresh media was added to cells every 24 hours. 
P19 embryonal carcinoma cells were obtained from American Type Culture 
Collection (ATCC). Cells were routinely maintained in Alpha-Mem (HyClone, Logan, UT) 
with 10% (v/v) fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 
nonessential amino acids (Sigma-Aldrich, St. Louis, MO) in a humidified incubator at 37° 
Celsius with 5% CO2 atmosphere. Cells were passaged every 1-3 days at a ratio between 
1:4 and 1:20. For passaging, cells were rinsed in phosphate buffered saline (PBS) (Sigma-
Aldrich, St. Louis, MO), incubated with 0.5% trypsin (Gibco, Invitrogen, Carlsbad, CA) for 
3-5 minutes, and centrifuged to pellet. Cells were then resuspended in complete media 
(as described earlier in this paragraph) and seeded into clean flasks with fresh media. 
Creation of E. Coli Based UAA Incorporation System 
Primers and stuff were used to create the plasmids ectRNA and ecRS, encoding 
wildtype E. coli tRNAtyr and wildtype E. coli aminoacyl tyrosyl tRNA synthetase 
respectively. Briefly. Correct sequences for each plasmid were confirmed by DNA 
sequencing (UT ICMB DNA Sequencing Facility, TX). 
DNA Constructs 
The plasmids 40TAG-peGFPN1, 312tRNA, and 309RS encoding the components 
of the M. jannaschii based UAA incorporation system were developed in Chapter Four 
and used for the investigations in this chapter. 
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Transfection and Amber Stop Codon Suppression Assays 
One important note about electroporation techniques: DNA must be quite 
concentrated in order to use the amounts necessary in the volume of a cuvette. Thus, all 
DNA prep utilized either Maxi or Mega Prep kits from Qiagen (Valencia, CA), and DNA 
was suspended at 1 µg/uL at a minimum. All DNA was sterile filtered in a laminar flow 
hood prior to use in transfection experiments. 
FugeneHD Transfection of HEK293T Cells 
FugeneHD was purchased from Roche (Switzerland). HEK293T cells were grown 
to 70-80% confluency in 6-well plates (Corning, Lowell, MA) and then cotransfected 
40TAG-peGFPN1 and each of the various tRNA constructs mentioned previously (i.e. 
each tested tRNA was transfected along with 40TAG-peGFPN1, not with other tRNAs). 
FugeneHD was used for transfection, and complexes were formed in Opti-Mem using a 
ratio of 2 µL FugeneHD to 1 µg DNA. Media was changed every 24 hours after 
transfection.  
Electroporation Transfection 
P19 embryonal carcinoma cells at 80% - 90% confluency were harvested using 
the same procedure as used for passaging, washed once with PBS (Sigma-Aldrich, St. 
Louis, MO), spun down again, and resuspended in 600 µL of PBS per harvested T-75 flask 
of cells. For each condition in an experiment, 200 µL of cells was aliquotted into an 
eppendorf tube. Then DNA appropriate for each condition was added to the cells. The 
total volume for each electroporation was then brought up to 450 µL by addition of PBS. 
Cell DNA mixtures were then transferred to electroporation cuvettes with a 2 mm gap 
(Fisher Scientific, Waltham, MA), and cuvettes were incubated on ice for no less than 5 
minutes and no more than 15 minutes before electroporation. Cell-DNA mixtures were 
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electroporated using a Bio-Rad Gene Pulser with capacitance extender and pulse 
controller (Bio-Rad, Hercules, CA) with settings of 270 Volts, 100 Ω, and 960 µF. After 
electroporation, cells were incubated on ice for at least 3 minutes and then 
resuspended in complete media. Cells were then plated in tissue culture vessels of the 
appropriate size (Corning, Lowell, MA). Media was changed 24 hours post-transfection 
and every 24 hours thereafter until experiments were completed. 
Hybrid FugeneHD + Electroporation Transfection 
Fugene HD was purchased from Roche (Switzerland). A modified version of 
Roche’s FugeneHD protocol was used for the hybrid transfection procedure. Instead of 
50 µL of diluent per µg of DNA, 25 µL of diluent was used per µg of DNA. Assuming the 
concentration of DNA were 1 ug/µL, the following protocol would be used. First, PBS is 
added to an eppendorf tube such that the final volume of PBS + DNA + FugeneHD will be 
25 uL/ug DNA. In this case that is 330 µL of PBS. Then 15 ug of DNA is added to the PBS, 
followed by 30 µL of FugeneHD. The tube is closed securely, vortexed, and incubated 
while cells are harvested. P19s at 80-90% confluency are harvested from a single T-75 
flask, washed in PBS, spun down, and resuspended in 900 µL of PBS. 300 µL of the cell 
solution is then aliquotted into an eppendorf tube and spun down. Once the 
supernatant has been aspirated from the eppendorf tube of P19s, the FugeneHD 
complexes should have been incubating for about 15 minutes. Once the FugeneHD 
complexes have incubated at room temperature for at least 15 minutes, the P19 cell 
pellet in the eppendorf tube is resuspended in Fugene complexes and transferred to an 
electroporation cuvette. 
 111 
Amber Stop Codon Suppression Assays 
HEK293T cells used for initial testing of the E. coli tRNA/RS pair were transfected 
with FugeneHD as described above. P19s were transfected with the elements of the two 
UAA incorporation systems using either the electroporation protocol, or the hybrid 
transfection protocol. Though DNA amounts had been previously optimized for each 
protocol, various amounts of DNA were tested for each UAA incorporation system to 
ensure the best triple transfection possible. In each case, media was changed 24 hours 
after transfection and every 24 hours thereafter. Cells were imaged every 24 hours after 
transfection using a Nikon Eclipse TE2000-S microscope with a FITC HyQ filter (Chroma, 
Rockingham, VT). Cells were harvested at either 72 hours or 96 hours post-transfection 
for fluorescence activated cell sorting (FACS). Briefly, the passaging protocol was 
followed up to the point of centrifugation. After centrifugation, cells were washed once 
in PBS and recentrifuged. PBS supernatant was aspirated, and cells were resuspended in 
4% paraformaldehyde in PBS (USB Corp. Cleveland, OH). Cells were incubated in 
paraformaldehyde for 15 minutes, then re-centrifuged. Paraformaldehyde was 
aspirated, and cells were resuspended in PBS then subjected to FACS. FACS was 
accomplished using a BD FacsCalibur, and data analysis was done using Cyflogic. For all 
FACS experiments, dead cells were excluded using forward and side scatter. GFP gating 
was done by designating the area of the GFP histogram occupied by untransfected cells 
as “GFP Negative,” and all cells exhibiting higher fluorescence than untransfected cells 
were classified as “GFP Positive.” 
Immunostaining for Differentiation Assays 
To ascertain the effect of the exogenous components of the UAA incorporation 
system(s), P19s were transfected with the E. coli tRNA/RS as per the conditions shown in 
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Figure 5.1. One condition was also transfected with the non-orthogonal M. jannaschii 
based amber suppressor tRNA. 48 hours after transfection, all conditions were 
harvested as detailed in the preceding section, and then they were sterile sorted with a 
BD Biosciences FacsAria to isolate and keep the GFP positive cells. As with previous FACS 
experiments, dead cells were excluded using forward and side scatter. GFP gating was 
done by designating the area of the GFP histogram occupied by untransfected cells as 
“GFP Negative,” and all cells exhibiting higher fluorescence than untransfected cells 
were classified as “GFP Positive.” GFP positive cells were collected in sterile, complete 
media with 20% (v/v) FBS. While sorting was still going on, sorted cells were kept on ice. 
The entire sorting process for these samples took approximately 4 hours. After sorting, 
cells were spun down and resuspended in complete media + Penstrep (Gibco, 
Invitrogen, Carlsbad, CA). Cells were then seeded in sterile, chambered coverglass 
(Fisher Scientific, Waltham, MA). Media was changed every 24 hours after cells were 
seeded. 48 hours after sorting, media was aspirated from cells. Each chamber was 
washed, very gently, with PBS. After aspirating the PBS, 4% paraformaldehyde in PBS 
was added to each chamber, and cells were incubated in paraformaldehyde for 10 
minutes. Paraformaldehyde was then aspirated, and cells were washed twice with PBS. 
Cells were then permeabilized by incubating in 0.25% Triton-X in PBS for 15 minutes at 
room temperature. Cells were then washed twice with PBS, followed by blocking with 
1% BSA (NEB, Ipswich, MA) in PBS for 1 hour at room temperature.  
The following procedure was followed for immunostaining. PBS + BSA was 
aspirated, and cells were then incubated with primary antibodies for neural cell 
adhesion molecule (NCAM), α-actinin, and Oct4. Mouse monoclonal anti- α-actinin was 
purchased from Sigma-Aldrich (St. Louis, MO), rat monoclonal anti-NCAM was 
purchased from GeneTex (Irvine, CA), and rabbit polyclonal anti-Oct4 was purchased 
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from Millipore (Billerica, MA). Primary antibodies were diluted in PBS according to the 
manufacturer’s instructions, and cells were incubated with the primary antibody 
solution overnight at 4°C. Samples were then washed three times with PBS, followed by 
incubation in the secondary antibody solution for 2 hours at room temperature. The 
secondary antibody solution was prepared by dissolving secondary antibodies in PBS 
according to the manufacturer’s instructions. All of the following secondary antibodies 
were purchased from Invitrogen (Carlsbad, CA): AlexaFluor® 594 chicken anti-rat, 
AlexaFluor® 532 goat anti-rabbit, and AlexaFluor® 405 goat anti-mouse. Secondary 
antibody solutions were protected from light as much as possible. After incubation, the 
secondary antibody solution was aspirated, and the samples were washed three times 
with PBS.  
Confocal Microscopy Imaging 
After immunostaining, samples were imaged with a Leica SP2 AOBS confocal 
microscope (Leica Microsystems Inc., Buffalo Grove, IL) in the UT ICMB Core Facility. 
AlexaFluor® 405 fluorescence was captured with the 405 nm laser at 24% power, and 
the corresponding photomultiplier (PMT) set to 493 volts.  AlexaFluor® 532 fluorescence 
was captured with the 543 nm laser at 25% power, and the corresponding 
photomultiplier (PMT) set to 597 volts.  AlexaFluor® 594 fluorescence was captured with 
the 594 nm laser at 24% power, and the corresponding photomultiplier (PMT) set to 570 
volts.  All images were averaged over eight frame captures to reduce noise, and all 
images were captured with a 40x oil objective during one microscope session. 
Fluorescence images were captured sequentially to minimize fluorophore cross-talk. 
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RESULTS AND DISCUSSION 
Amber Stop Codon Suppression Using the E. coli System 
To confirm the functionality of the E. coli tRNA and RS, they were first used in 
HEK293T cells. Figure 5.1 demonstrates the excellent functionality of the E. coli tRNA/RS 
pair. 
Unsurprisingly, the E. coli tRNA condition exhibits some fluorescence. Since FACS 
was not done on these cells, it is difficult to quantify the level of background created by 
the E. coli tRNA. Even without the quantitative data, this particular experiment 
demonstrates that exogenous, bacterial tRNA is recognized by some endogenous RSs in 
HEK293T cells, once again pointing to the hitherto underestimated complexity of tRNA 
identity determinants. Despite the imperfect orthogonality of the E. coli tRNA, when in 
the presence of E. coli RStyr, this tRNA is clearly charged and able to suppress amber stop 
codons, as evidenced by the suppression image in Figure 5.1. In fact, the suppression 
Figure 5.1: Fluorescent images demonstrating functionality of E. coli based UAA 
Incorporation System in HEK293T cells transfected with the DNA constructs 
below each image, as described on page 109. All images were captured 48 
hours after transfection with gain set to 1 and exposure time set to 1 second. 
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condition appears to obtain between 30% and 50% of the eGFP expression achieved by 
transfection with peGFP-N1.  
Without directly comparing this data to the previously developed M. jannaschii 
tRNA/RS pair, it could have been difficult to gauge whether or not to pursue one or both 
UAA incorporation systems. Thus, another experiment was done so that the cells could 
be assessed via FACS. In order to compare the E. coli and M. jannaschii systems directly, 
the respective experiments were normalized to the fluorescence level measured from 
cells transfected only with 40TAG-peGFPN1.  
Figure 5.2: Fluorescence intensity fold change as determined by analysis of FACS data 
for HEK293T cells transfected with the E. coli or M. jannaschii based UAA 
incorporation system components. Cells for each sample were harvested 48 
hours post transfection, and fold change is defined as (sample 
fluorescence)/(40TAG-peGFPN1 fluorescence). 
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Figure 5.2 demonstrates the clear differences between the E. coli tRNA/RS pair 
and the previously developed M. jannaschii based tRNA/RS pair. While the tRNAmjtyr 
exhibits almost 3 times the fluorescence of the 40TAG-peGFPN1 control, the tRNAectyr 
exhibits almost exactly the same fluorescence as that control. In contrast, the E. coli pair 
exhibits almost eight times the fluorescence of the control, whereas the M. jannaschii 
based pair achieves just less than four times the control. Even more stark is the 
difference between the respective tRNA background and suppression efficiencies of the 
two systems. The E. coli suppression condition achieves almost eight times the 
fluorescence caused by tRNA background, whereas the M. jannaschii suppression 
condition achieves less than twice the fluorescence caused by its tRNA background. 
Clearly then, the E. coli pair is a better choice, except for the lack of readily available 
synthetases. While the amino acid sequences for E. coli based synthetases are known, 
none of those synthetases are preexisting in our lab. Thus, based upon the information 
presented in Figure 5.1and Figure 5.2, it seemed the most expedient route was to 
pursue the use of both systems. Thus, in the event that the M. jannaschii pair was 
successful in P19s, we could move immediately to UAA incorporation in those cells. If 
not, we would be working on making the UAA specific synthetases from the E. coli 
synthetase while testing the two systems in P19s. 
There is one more key point that must be made about the preceding data. In 
HEK293T cells, when coexpressing an amber suppressor tRNA based upon a wildtype 
tRNA and a wildtype tRNA synthetase, those two elements are unable to achieve the 
expression efficiency of endogenous tRNAs. I.e. endogenous tRNAs are able to produce 
far more wildtype GFP from the peGFP-N1 plasmid than the single exogenous amber 
suppressor tRNA and cognate synthetase can produce from a nearly identical plasmid 
with a single point mutation. This is an important limitation of a UAA incorporation 
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system as it highlights the difficulty of introducing foreign DNA or proteins to a cell or 
organism and coaxing to behave as endogenous materials, and it also points to the fact 
that alterations to tRNAs and synthetases logically decrease the efficiency of their 
interactions. Regardless, both the M. jannaschii based UAA incorporation system and 
the E. coli system functioned reasonably well in HEK293T cells, so they were both tested 
in P19s. 
Amber Stop Codon Suppression in P19s with the M. jannaschii Based System 
P19s were electroporated with the components of the M. jannaschii based UAA 
incorporation system, 312tRNA, 309RS, and 40TAG-peGFPN1. As with all other 
transfection based experiments, GFP expression was assessed via fluorescence 
microscopy at 24 and 48 hours post transfection, and cells were harvested and 
subjected to FACS at 48 hours post transfection. As shown in Figure 5.3, the M. 




Figure 5.3: Fluorescent images demonstrating functionality of M. jannaschii based UAA 
Incorporation System in P19s electroporated with 100 µg each of the DNA 
constructs below each image. All images were captured 48 hours after 
transfection with gain set to 1 and exposure time set to 1 second. In each 
image, cells are approximately 50% confluent. 
 118 
Only one fluorescent cell is evident in the suppression condition shown in Figure 
5.3. This result could have been indicative of low transfection efficiencies, but the 
positive control effectively demonstrates that transfection efficiency was not a problem. 
In fact, the cells in each condition are approximately 50% confluent, which means that, 
based upon the images in Figure 5.3, the transfection achieved higher than 70% 
efficiency. If the M. jannaschii tRNA and synthetase pair function in P19s as they do in 
HEK293T cells, then one could reasonably expect fluorescence exhibited by suppression 
conditions to proportionately decrease with overall transfection efficiency. In Chapter 
Four, data was presented indicating that HEK293T cells transfected with the 
components of the M. jannaschii tRNA/RS pair achieve approximately 27% of the 
fluorescence exhibited by positive controls. Thus, in the case of P19s, we might expect 
27% of 70% (fluorescent cells in positive control) of the total cells to express enough 
GFP to be detected by fluorescent microscopy. That means that if the system works in 
P19s as it does in HEK293T cells, we would see about 19% of the total cells in a given 
image as fluorescent. If there were only five cells in the suppression condition image, 
that could indicate functionality of the M. jannaschii pair in P19s. Unfortunately there 
are hundreds of cells in that image, and yet only one has expressed a detectable amount 
of GFP.  
We posited that perhaps P19s did not respond to the promoters in the system, 
those for protein as well as for tRNA. While this may have been the case for the tRNA 
plasmid, it probably was not the case for the RS or 40TAG-peGFPN1 plasmids, as they 
have either identical or almost identical promoters to the peGFP-N1 plasmid which 
clearly produced functional GFP protein in this cell line. Thus, we tested the tRNA 
transcription by creating a non-orthogonal tRNA, specifically a wildtype M. jannaschii 
tRNAtyr with an amber anticodon. By transfecting cells with this nonorthogonal amber 
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suppressor tRNA and 40TAG-peGFPN1, GFP fluorescence could be used as an indicator 
of successful tRNA synthesis in P19s.  
As evidenced by the Non-orthogonal tRNA column in Figure 5.4, P19s do 
synthesize tRNA when transfected with a plasmid bearing the human H1 promoter 
upstream of a tRNA gene. In comparison to the peGFP-N1 positive control, the non-
orthogonal tRNA + 40TAG-peGFPN1 condition appears to achieve approximately the 
same level of fluorescence as the positive control. However, cell viability in the non-
orthogonal tRNA condition does appear to be compromised. This may indicate a 
Figure 5.4: Fluorescent images demonstrating non-orthogonal tRNA synthesis by P19 
cells transfected with 50 µg each of non-orthogonal tRNA and 40TAG-
peGFPN1, or in the case of the peGFP-N1 column, 100 µg of peGFP-N1. 
Fluorescence images were captured 48 hours after transfection with gain set 
to 1 and exposure time set to 1 second. The contrast in the merged images 
FITC channel has been increased by 88% to facilitate visualization. 
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hitherto unexpected complication of expressing amber suppressor tRNA in pluripotent 
cell lines, namely, that overexpression of amber suppressor tRNA compromises cell 
viability. Though we have not seen this same phenomenon in HEK293T cells, it is 
conceivable that amber suppression releases fusion proteins or transcription factors 
which can only effectively activate apoptotic pathways in pluripotent cell lines.  
Successful amber suppression via tRNA recognition by endogenous P19 
synthetases indicates that there are fundamental differences between the protein 
translational machinery components in P19s and HEK293Ts. Since exogenous tRNA can 
clearly be produced and charged with amino acids, the problem cannot be simply a 
complete lack of tRNA transcription. Though it may be that P19s do not complete post-
transcriptional modifications to tRNA fragments in the same manner as HEK293Ts, 
rendering tRNAs produced within these cells compatible only with P19 synthetases or 
only moderately compatible with exogenous synthetases. To fully understand the 
mechanism behind the stark difference in amber suppression with a non-orthogonal 
tRNA and endogenous synthetase versus amber suppression using the previously 
developed M. jannaschii based orthogonal tRNA/RS pair would require a great deal of 
further study. Since it became clear that P19s could produce functional exogenous 
tRNA, we chose to move forward and test the E. coli tRNA/RS pair since they performed 
better in HEKs (better meaning achieved higher fluorescence) than the M. jannaschii 
pair. 
Amber Stop Codon Suppression in P19s with the E. coli Based System 
P19s were electroporated with the E. coli amber suppressor tRNA and wildtype 
synthetase (ectRNA and ecRS) to determine their functionality in P19s. GFP expression 
was assessed using fluorescence microscopy and FACS. 
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As shown in Figure 5.5, above, the E. coli tRNA/RS pair does successfully 
suppress amber stop codons in P19s, with a much greater degree of success than the M. 
jannaschii pair. Without doing any further experiments, these images demonstrate 
squarely that the amber suppressor tRNA and RS from E. coli can be functionally 
expressed in P19s, and this tRNA/RS pair can work together to suppress amber stop 
codons. As evidenced by the brightfield images in Figure 5.5 A, there is a negative effect 
on cell viability which correlates with exogenous amber suppressor tRNA transfection. 
Figure 5.5: A) Fluorescent images demonstrating amber stop codon suppression by P19s 
transfected with the E. coli based plasmids listed. B) Multiple merged 
brightfield+fluorescence images taken from the sample shown in the E. coli 
suppression condition of part A. All images were captured 48 hours after 
transfection with gain set to 1 and exposure time set to 1 second. 
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Though some studies have indicated increased cell mortality rates when mammalian 
cells are transfected with high levels of DNA, the positive control in this case rules out 
the role of ‘DNA poisoning’ in the increased cell mortality rates. The suppression 
condition and the positive control condition each used the same total amount of DNA, 
while the 40TAG-peGFPN1, E. coli tRNA, and E. coli suppression conditions each utilized 
the same amount of DNA per construct. Since this phenomenon of decreased cell 
viability in tRNA containing transfections is consistent across experiments with M. 
jannaschii orthogonal and non-orthogonal tRNA and E. coli tRNA, there likely is some 
mechanism for which tRNA synthesis is serving as the impetus. Regardless, the number 
of surviving cells as well as the efficiency of suppression appears high enough to warrant 
continued pursuit of the E. coli based system. 
To that end, P19 cells transfected with the components of the E. coli based UAA 
incorporation system, exactly as shown in Figure 5.5, were harvested 48 hours post-
transfection and subjected to FACS. Figure 5.6 below shows the results of the first of 
many identical experiments. There are several important pieces of information in this 
figure, the first of which is that the E. coli suppression condition exhibits 27 times the 
fluorescence intensity of the 40TAG-peGFPN1 condition and slightly less than 4 times 
the fluorescence intensity of the tRNA control condition. The first number is of little 
consequence, but quadrupling the fluorescence signal from the tRNA control condition 
is a substantial accomplishment, especially in light of the fact that this increase over 
control is fully half of that seen in HEK293T cells. Since people have successfully used 
systems like these in HEK293T cells, this result is encouraging, and demanded further 
pursuit of the E. coli based system. Additionally, the suppression condition achieved 
approximately 10% of the fluorescence level of the positive control. While this number 
may seem low, we consider it an accomplishment. For our system to produce full length 
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GFP requires the functional expression of both tRNA and synthetase prior to expression 
of GFP, while the positive control can express GFP using the preexisting endogenous 
protein translational machinery. Thus, we chose to further investigate the effects of 
these exogenous materials on the differentiation state of P19s. 
 
Differentiation Assays 
To assess the effect of the E. coli based UAA incorporation system on the 
differentiation state of P19s, cells were electroporated with the components of the 
system, and then they were sterile sorted by FACS. Cells expressing GFP were grown for 
Figure 5.6: Fluorescence intensity of P19s expressing components of the E. coli based 
UAA incorporation system, as determined by analysis of FACS.  
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another day on chambered coverslips. They were then fixed, permeabilized, and 
immunostained for differentiation and pluripotency markers. For conditions with very 
small or nonexistent populations of GFP expressing cells, cells not expressing GFP were 
used for staining. For instance, the cells transfected with ectRNA and 40TAG-peGFPN1 
were not expected to fluoresce upon successful expression of the protein/tRNA 
encoded by their plasmids. Thus, testing the non-fluorescent cells in those conditions 
was the only real and logical option.  
As shown in Figure 5.7, cells in all conditions stain positively for Oct4, which is a 
marker of pluripotency in many stem cell lines, including P19s (4). Cells were not 
counterstained with any nuclear or membrane permeant stains, because all available 
stains would have interfered with either the secondary antibody fluorescence or the 
GFP fluorescence. Since we wanted to investigate the relationship between cells 
successfully expressing the exogenous tRNA and/or RS, the GFP signal needed to be 
differentiable from all others. Thus, it is difficult to discern cell boundaries in these 
images. Furthermore, brightfield images were unable to effectively capture cell 
boundaries either. Thus, only GFP and the AlexaFluor® dyes are visible in these images. 
Nevertheless, they provide a wealth of information. From the GFP column in Figure 5.7, 
one can ascertain that it was impossible to find cells exhibiting GFP fluorescence in 
either the E. coli tRNA condition or the No DNA condition, but all three other conditions 
did contain GFP expressing cells. This further corroborates the previous fluorescence 
images and FACS data indicating that the non-orthogonal amber suppressor tRNA can 
be synthesized and used by endogenous synthetases to suppress the TAG codon in 





























Figure 5.7: Pseudocolored confocal images of immunostained P19s transfected with 
exogenous tRNA(s) and synthetases, or appropriate controls, as noted on the 
left hand column. All images were captured with the same microscope 
settings from the same experiment. 
20 µm 
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Though there is some very light fluorescence in the range of the NCAM antibody 
dye in the non-orthogonal tRNA condition, that is most likely not indicative of 
differentiation as the same light staining appears in the negative control (No DNA). 
There was no discernible staining due to α-actinin, indicating that these cells are most 
likely not differentiation down any skeletal muscle pathways. Overall, there appears to 
be no difference in staining in the control conditions as compared to the exogenous 
tRNA/RS conditions. This indicates that P19s can produce and use exogenous tRNAs and 
RSs to suppress stop codons, and that process most likely is not inducing differentiation.  
Some may argue that 96 hours post-transfection is too soon to assess 
differentiation. However, in terms of P19 differentiation, it is well established in the 
literature that P19s exhibit discernible and often irreversible differentiation as early as 
24 hours after induction of differentiation (4, 5). Thus, assessing differentiation 96 hours 
post-transfection, as far as the relevant literature is concerned, should be a fairly 
reliable method. However, since these cells have to actually express several 
components before they can have an effect on differentiation, if they have an effect, it 
could be that differentiation markers would be slightly delayed. While further study 
could confirm this, our controls appeared no different than the tRNA/RS conditions, so 
we felt it unnecessary to further investigate their ability to differentiate P19s at this 
time. It is possible that certain UAAs could exert some effect on differentiation state, at 
which point it will be logical to pursue another differentiation study. 
MORPHOLOGICAL AND VIABILITY CHANGES RESULTANT FROM AMBER SUPPRESSION 
In both the E. coli and M. jannaschii amber suppression conditions shown in 
Figures 5.3 - 5.7, there are dramatically fewer surviving cells than in the negative and 
positive control conditions. While no cell proliferation assays were performed, the 
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images clearly demonstrate that amber suppression has deleterious effects on P19s. 
While these effects did not prevent completion of the experiments detailed in this 
dissertation, they do give some pause as to the future of projects along these lines. 
Amber stop codons in the 40TAG-peGFPN1 gene are suppressed by these systems, but 
so too are amber stop codons within the P19 genome, resulting in protein polymers 
which exceed the length of normal proteins. This situation logically results in proteins 
which do not fold properly or in fact have completely different functions than intended, 
resulting in decreased cell viability. Without further study, it is impossible to determine 
exactly how much amber suppression P19s can accomplish without compromising cell 
viability to the degree seen thus far in this project. Until such work is done, the 
usefulness and feasibility of UAA incorporation in response to amber stop codon 
suppression in P19s will remain unknown. 
CONCLUSION 
In the preceding pages, data has been presented indicating each of the 
following: 
1. E. coli based amber suppressor tRNA and wildtype RS can achieve amber 
stop codon suppression in P19s. 
2. E. coli based amber suppressor tRNA and wildtype RS are substantially 
more efficient in P19s than the M. jannaschii derived pair. 
3. Expression of exogenous tRNAs and/or synthetases does not induce 
discernible differentiation by 4 days post-transfection. 
4. Amber suppression appreciably compromises P19 cell viability. 
From this information we can draw a few more conclusions. First of all, the E. coli 
system is certainly worth pursuing, as it works so well and produces enough UAA 
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incorporation system expressing cells that a population of them can be isolated for 
further testing by FACS. Implementation of the E. coli based UAA incorporation system 
in mammalian cells could swiftly enable a variety of UAA based studies in the P19 or 
other pluripotent cell environments, especially if that work involves collaborations with 
other investigators with experience using the E. coli synthetases. Second, exogenous 
synthetases and tRNAs do not appear to be inducing differentiation, meaning that UAA 
incorporation systems could be employed in the study of normal differentiation 
processes. Finally, since it would take time to develop the UAA specific synthetases for 
E. coli tRNAs, and there were fluorescent cells in the M. jannaschii system, we chose to 
pursue both the E. coli system and the M. jannaschii system concurrently. The reason 
for this stems from the experience of several lab members with UAA incorporation in 
other organisms. It has been their experience that UAA specific synthetases often 
perform better than expected based upon those evolved simply for amber anticodon 
permissivity. Thus, we chose to pursue actual incorporation of UAAs (as opposed to the 
amber suppression studies presented in the preceding pages) using the M. jannaschii 
system to see if a UAA specific synthetase could charge the amber suppressor tRNA 
more efficiently than the tyrosyl-RS. Thus, UAA incorporation using the M. jannaschii 
based synthetases, and creation of E. coli based UAA specific synthetases will be 
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Incorporation of Unnatural Amino Acids into Proteins in P19 Embryonal 
Carcinoma Cells 
INTRODUCTION 
Unnatural amino acids (UAAs) have been used in a variety of applications 
including, but not limited to, protein-tagging, site-specific post-translational 
modification mimicking, and protein structure/function assays (1-5). The preceding 
chapters have detailed the development and testing of UAA incorporation systems for 
use in all mammalian cells, but in the scope of this dissertation they have been applied 
to P19 embryonal carcinoma cells (P19s) with the intent that they will eventually be 
deployed in other pluripotent or stem cell lines. Chapter Five described the use of a 
Methanocaldococcus jannaschii (M. jannaschii) based amber suppressor tRNA and 
aminoacyl tRNA-synthetase (RS) pair and an Eschericia coli (E. coli) based amber 
suppressor tRNA/RS pair for amber stop codon suppression in both HEK293T cells and 
P19 embryonal carcinoma cells. Based upon the success of the E. coli tRNA/RS pair, we 
chose to continue investigation along those lines by developing a UAA specific RS from 
the E. coli RS, after which we could use that RS to incorporate UAA(s) into proteins in 
P19s. Since the M. jannaschii tRNA/RS pair functioned, though at a low level, we chose 
to move forward and test the previously developed M. jannaschii derived UAA specific 
synthetases in P19s, because previous experience has shown that some UAA specific 
synthetases are actually more efficient at charging amber suppressor tRNAs than their 
canonical amino acid charging counterparts (personal communications).  
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Overall Experimental Design 
To accomplish the goal of incorporating UAAs into proteins in P19s, the following 
experimental goals were set: 
1. Create and test an E. coli derived RS specific for the incorporation of the 
UAA m-acetyl-L-phenylalanine (pketo) in P19s. 
2. Test the previously developed M. jannaschii tRNA/RS pair specific for 
pketo incorporation. 
The first goal will involve site-directed mutagenesis of the RS developed in 
Chapter Five. The second will require simple application of the previously developed M. 
jannaschii tRNA with a cognate RS specific for incorporation of pketo. Hydrazide staining 
will be used to confirm the incorporation of pketo into proteins in P19s. 
MATERIALS AND METHODS 
Routine Cell Culture 
P19 embryonal carcinoma cells were obtained from American Type Culture 
Collection (ATCC). Cells were routinely maintained in Alpha-Mem (HyClone, Logan, UT) 
with 10% (v/v) fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 
nonessential amino acids (Sigma-Aldrich, St. Louis, MO) in a humidified incubator at 37° 
Celsius with 5% CO2 atmosphere. Cells were passaged every 1-3 days at a ratio between 
1:4 and 1:20. For passaging, cells were rinsed in phosphate buffered saline (PBS) (Sigma-
Aldrich, St. Louis, MO), incubated with 0.5% trypsin (Gibco, Invitrogen, Carlsbad, CA) for 
3-5 minutes, and centrifuged to pellet. Cells were then resuspended in complete media 
and seeded into clean flasks with fresh media. 
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DNA Constructs 
The plasmids encoding 40TAG-eGFP (40TAG-peGFPN1 plasmid) and M. 
jannaschii based amber suppressor tRNA (312tRNA plasmid) and chimeric tyrosyl RS 
(309RS plasmid) were described in the preceding chapters. The pketo specific chimeric 
RS (plasmid pketoMJRS) was a gift from a colleague.  
Hybrid FugeneHD + Electroporation Transfection 
Fugene HD was purchased from Roche (Switzerland). A modified version of 
Roche’s FugeneHD protocol was used for the hybrid transfection procedure. Instead of 
50 µL of diluent per µg of DNA, 25 µL of diluent was used per µg of DNA. Assuming the 
concentration of DNA were 1 ug/µL, the following protocol would be used. First, PBS is 
added to an eppendorf tube such that the final volume of PBS + DNA + FugeneHD will be 
25 uL/ug DNA. In this case that is 330 µL of PBS. Then 15 ug of DNA is added to the PBS, 
followed by 30 µL of FugeneHD. The tube is closed securely, vortexed, and incubated 
while cells are harvested. P19s at 80-90% confluency are harvested from a single T-75 
flask, washed in PBS, spun down, and resuspended in 900 µL of PBS. 300 µL of the cell 
solution is then aliquotted into an eppendorf tube and spun down. Once the 
supernatant has been aspirated from the eppendorf tube of P19s, the FugeneHD 
complexes should have been incubating for about 15 minutes. Once the FugeneHD 
complexes have incubated at room temperature for at least 15 minutes, the P19 cell 
pellet in the eppendorf tube is resuspended in Fugene complexes and transferred to an 
electroporation cuvette. 
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Unnatural Amino Acid Incorporation Assays 
Transfection and Fluorescence Microscopy Incorporation Assessment 
P19s were transfected using the above hybrid FugeneHD + electroporation 
method with 40TAG-peGFPN1, 312tRNA, and pketoMJRS. Media was changed every 24 
hours after transfection, and fluorescent images were captured daily immediately prior 
to media changes. Fluorescent images were captured using a Nikon Eclipse TE2000-S 
microscope with a FITC HyQ filter (Chroma, Rockingham, VT). 48 hours after 
transfection, cells were harvested and split into two samples per experimental 
condition, one for fluorescence activated cell sorting (FACS), and one for western 
blot/hydrazide modification. For FACS sorting, the passaging protocol was followed up 
to the point of centrifugation. After centrifugation, cells were washed once in PBS and 
recentrifuged. PBS supernatant was aspirated, and cells were resuspended in 4% 
paraformalehyde in PBS (USB Corp. Cleveland, OH). Cells were incubated in 
paraformaldehyde for 15 minutes, then re-centrifuged. Paraformaldehyde was 
aspirated, and cells were resuspeded in PBS then subjected to FACS. FACS was 
accomplished using a BD FacsCalibur, and data analysis was done using Cyflogic. For all 
FACS experiments, dead cells were excluded using forward and side scatter. GFP gating 
was done by designating the area of the GFP histogram occupied by untransfected cells 
as “GFP Negative,” and all cells exhibiting higher fluorescence than untransfected cells 
were classified as “GFP Positive.” 
Western Blot and Hydrazide Modification 
For western blot/hydrazide staining, cells were pelleted after harvest and 
resuspended in M-PER mammalian protein extraction reagent (Thermo-Scientific, 
Waltham, MA) with 1X Complete mini protease inhibitor (Roche, Switzerland). Both M-
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Per and the complete mini protease inhibitor were used according to the 
manufacturer’s instructions. Lysis mixtures were incubated with gentle shaking at room 
temperature for 10 minutes followed by centrifugation at 14,000xg for 15 minutes to 
pellet cell debris. At this point, all samples not intended for hydrazide modification were 
refrigerated at 4°C until gel electrophoresis could be completed.  
For hydrazide modification intended samples, supernatant was removed from 
centrifuged samples and dialyzed into PBS overnight. After dialysis, samples were 
hydrazide modified as follows. AlexaFluor® 633 hydrazide was purchased from 
Invitrogen (Carlsbad, CA) and dissolved in 200mM KCl. Dialyzed samples were removed 
from dialysis membranes and placed in microcentrifuge tubes. AlexaFluor® 633 
hydrazide solution was then added to microcentrifuge tubes, and the samples were 
incubated at 4°C for 16 hours. After incubation with hydrazide, samples were dialyzed 
into ammonium bicarbonate buffer (pH 7.2) for 24 hours to remove unreacted 
hydrazide. Samples were then lyophilized overnight and resuspended in PBS. After 
resuspension, samples were subjected to SDS-polyacrylamide gel electrophoresis (SDS-
PAGE). Total protein concentrations were the same in each lane, and non-hydrazide 
reacted samples were subjected to SDS-PAGE simultaneously with hydrazide reacted 
samples.  
Protein was blotted onto nitrocellulose using an iBlot (Invitrogen, Carlsbad, CA). 
Membranes were blocked in 1% dry milk in TBST followed by probing with Clontech 
Living Colors anti-eGFP primary antibody (Clontech, Mountainview, CA). The secondary 
antibody, goat-anti-mouse horseradish peroxidase (HRP) conjugate was purchased from 
BioRad (Hercules, CA). GFP was detected using Amersham ECL Plus detection reagents 
(GE Healthcare, Piscataway, NJ). 
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Creation of pketo Specific E. coli RS 
Site-directed mutagenesis was used to introduce the necessary mutations to the 
previously developed ecRS plasmid. 
RESULTS AND DISCUSSION 
Pketo Incorporation with the M. jannaschii tRNA/RS Pair 
Figure 6.1 below shows the FACS results of the first two pketo incorporation. 
Figure 6.1: Fluorescence intensity of P19s expressing components of the M. jannaschii 
based pketo incorporation system, as determined by analysis of FACS. Only 
columns denoted with ‘+ pketo’ were grown in the presence of pketo. 
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experiments. From this data (Figure 6.1), it appears that addition of pketo to conditions 
with exogenous tRNA dramatically decreases the fluorescence of these cells. 
Furthermore, as evidenced by the almost unbelievably high percentage of fluorescent 
cells in the Incorporate condition (without pketo), the pketo RS seems to be highly 
capable of charging the amber suppressor tRNA with canonical amino acids. In fact, in all 
previous experiments, not even positive controls (except for those used during single 
plasmid optimization experiments detailed in Chapter Three) have achieved GFP 
expression this high. Thus, armed with data indicating that the pketo specific RS was not 
specific for pketo, and that addition of pketo to cells somehow decreased the detectable 
levels of GFP, we came to the only logical conclusion: the samples had somehow been 
mislabeled. That must be followed by the assertion that two separate experiments were 
FACS sorted at the same time, and all samples are labeled meticulously. Thus, the 
likelihood of this type of mistake was almost 0. Nonetheless, it was more likely, 
scientifically speaking, than the pketo RS functioning almost completely incorrectly, and 
the pketo UAA inexplicably decreasing overall fluorescence of treated samples. 
Therefore, the samples were run again, and labeling of tubes was triple checked prior to 
transporting them to the FACS room. 
The second measurement of carefully labeled samples revealed that the first 
round of FACS samples were labeled correctly. Again, the conditions with pketo in the 
media exhibited substantially lower fluorescence than their corresponding non-pketo 
conditions, and the incorporation condition without pketo neatly outpaced the 
fluorescence of the positive control. Of note is the contradictory nature of this data in 
comparison to the fluorescence images. In the images, the most fluorescent condition is 
the positive control, followed by the non-orthogonal tRNA condition and then the 
incorporation with and without pketo. Since FACS is more sensitive than fluorescence 
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microscopy, it is possible that it is legitimately detecting GFP expression levels which 
simply cannot be appreciated in the images. After discussing this with several colleagues 
it was determined that multiple experiments had been completed using this same 
Figure 6.2: Fluorescence intensity of P19s expressing components of the M. jannaschii 
based pketo incorporation system, as determined by FACS analysis. 
Fluorescence intensities were averaged over two experiments, each 
measured twice. Only columns denoted with ‘+ pketo’ were grown in the 
presence of pketo. 
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synthetase and tRNA pair and the same pketo, but across different cell lines with 
different transfection techniques, and all had yielded the same unexpected results. 
Fluorescence microscopy detected very little difference between incorporations with 
and without pketo, but FACS consistenly detected dramatically higher fluorescence in 
the incorporate condition without pketo than in any other condition, including positive 
controls for all samples. With that in mind, it became evident that the M. jannaschii 
based pketo specific RS was somehow increasing the fluorescence of cells in which it 
was expressed, and pketo was legitimately decreasing fluorescence in all cells 
transcribing exogenous amber suppressor tRNA. 
While there are certainly a variety of explanations for this phenomenon, the 
most likely is that GFP is being expressed at low levels in cells transfected with 40TAG-
peGFPN1, 312tRNA, and pketoMJRS. Either GFP fluorescence or GFP folding is then 
disrupted in cells which are grown in the presence of pketo. The design of this UAA 
incorporation system, at this stage, directs incorporation of pketo at the 40th amino acid 
in eGFP. This amino acid is not part of the UV core and is surface accessible. Thus, 
incorporation at the designated location would not be expected to decrease 
fluorescence. However, it has been shown that mutations in or near the UV core of GFP 
can disrupt folding and effectively knock down fluorescence despite expression of full 
length protein. Thus, if pketo were somehow being incorporated in locations other than 
the designated 40th amino acid, then it is logical that this mutation could effectively 
prevent proper folding of GFP and subsequent fluorescence measurements.  
The question then becomes: could pketo be incorporated at locations other than 
the designated 40th amino acid? As the Tirrell group has aptly demonstrated, cells 
deprived of a certain amino acid will incorporate unnatural analogs of that amino acid 
into all synthesized proteins, provided that they have no means of synthesizing the 
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deprived amino acid (6). In these deprivation type experiments, the concentration of 
UAA in the media is 1 mM. In contrast, the experiments represented by Figure 6.1 and 
Figure 6.2 used 5 mM pketo, but we did not deprive the cells of any natural amino acids. 
However, according to the manufacturer’s product information, L-tyrosine is at 0.231 
mM in the media, and L-phenylalanine is at 0.194 mM in the media. Thus, a 
concentration of 5 mM pketo in the media is more than 20X the concentration of L-
tyrosine and 25X the concentration of L-phenylalanine in the media. Since pketo is most 
similar to phenylalanine, it could be that an endogenous phenylalanyl synthetase is 
mistakenly charging phenylalanyl tRNAs with pketo. Since the concentration of pketo is 
so many fold higher than that of phenylalanine, it could be ‘flooding the system’ and 
increasing the likelihood of this mischarging. Since the Tirell group has demonstrated 
repeatedly that endogenous synthetases can mistakenly charge endogenous tRNAs with 
UAAs if they are present while a canonical amino acid is absent, there is some evidence 
to suggest that mischarging of endogenous tRNAs with pketo could be happening in 
these experiments. If that were the case, then GFP fluorescence could be compromised 
by indiscriminate/random incorporation of pketo. This could explain the apparent 
decrease in fluorescence between non-pketo and pketo containing conditions. However, 
this still does not account for the high fluorescence exhibited by incorporation 
conditions in the absence of pketo. 
In other UAA incorporation experiments, researchers have spent months, some 
years, in multiple rounds of positive and negative selections in which a whole enzyme 
was screened with libraries in only certain portions of the enzyme (7, 8). That is in 
contrast to what has been done in this research where pieces of enzymes were stitched 
together to create orthogonality as well as UAA specificity. Since the pketo RS used in 
the preceding experiments is this chimeric stitched together enzyme, incorporating 
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pieces of various other enzymes, it has not undergone any positive or negative 
selections. That being the case, this enzyme is unproven. Based upon the data shown in 
Figure 6.1 and Figure 6.2, this enzyme may have lost specificity for pketo or it may have 
been made permissive such that it accepts multiple amino acids or amino acid 
analogues as substrates. If this were the case, it would explain the increased 
fluorescence in the incorporation without pketo conditions. Coupled with the possibility 
that the concentration of pketo is high enough to persuade endogenous synthetases to 
charge endogenous tRNAs with it, these two possibilities together could explain the 
curious results shown thus far. However, it must be stated that there is no conclusive 
evidence by which one could draw a reasonably justified conclusion as to the 
mechanisms underlying the results. It can be determined that the amber suppressor 
tRNA and pketo RS do not function as anticipated and certainly do not appear to be site-
specifically incorporating pketo into the amber stop codon in the 40th position of GFP. 
In light of these confusing results, we chose to pursue the one available avenue 
to clarify the mechanism behind these results. With two final experiments, we 
attempted to incorporate pketo site-specifically into 40TAG-eGFP in P19s, and we chose 
to probe for site-specific incorporation (or lack thereof) by hydrazide modification of the 
keto functional group. As with the previous experiments, P19s were transfected with 
the components of the M. jannaschii based pketo incorporation system, and conditions 
were split after electroporation and treated with either no pketo or 10 mM pketo. A 
small sample of each was subjected to FACS, results shown in Figure 6.3, and an entire 
T-75 flasks’s worth of cells for each condition were then used for hydrazide 
modification. After hydrazide modification, successful site-specific incorporation of 
pketo would show the presence of AlexaFluor® conjugated hydrazide at the molecular 
weight of GFP after samples were subjected to SDS-PAGE, and the same band would 
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appear in a western blot probing for GFP. If pketo was incorporated into no proteins, 
then there should be no hydrazide presence in the gel, and finally if pketo were 
incorporated randomly due to the overwhelming concentration of pketo in the cells, 
there should be hydrazide staining in a smear across multiple molecular weights in the 
cell lysate.  
Based upon the percentage of fluorescent cells shown in Figure 6.3 we can 
ascertain, once again, that addition of pketo to the medium of P19s transfected with 
Figure 6.3: Fluorescence intensity of P19s expressing components of the M. jannaschii 
based pketo incorporation system, as determined by FACS analysis. 
Fluorescence intensities were averaged over two experiments, each 
measured twice. Only columns denoted with ‘+ pketo’ were grown in the 
presence of pketo. 
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exogenous amber suppressor tRNAs reduces measureable fluorescence. Once again, the 
incorporation condition without pketo in the media exhibited the highest percentage of 
GFP positive cells. Of note is the fact that the ectRNA + pketo condition exhibits half the 
fluorescence of the incorporate + pketo condition, indicating that co-expression of 
pketoMJRS with 312tRNA increases amber stop codon suppression. This gave us hope 
that hydrazide modification would demonstrate that pketo was in fact site-specifically 
incorporated into the reporter protein encoded by 40TAG-peGFPN1. 
Figure 6.4: Fluorescence scan of SDS-PAGE gel used to separate hydrazide labeled proteins 
(1) Cell lysate from non-orthogonal tRNA condition (2) hydrazide modified cell 
lysate from incorporate + pketo condition (3) hydrazide modified cell lysate 
from peGFP-N1 + pketo condition. Scans were acquired with a Typhoon Trio 
scanner with 532 nM excitation, a 610nm bandpass filter, and power set to 300 
V. 
 143 
The grey, pixilated portions of lanes 1 and 2 in Figure 6.4 are indicative of 
extremely high fluorescence and are an artifact of the imaging technique. The high 
fluorescence in these two lanes demonstrates that cell lysate from conditions with and 
without exogenous tRNAs or RSs are hydrazide modified when pketo is included in the 
media. Since the signal in this image was so high, as the protein loading was very high, it 
was difficult to discern whether or not there was a distinguishable band of hydrazide 
labeling in the range of GFP molecular weight. Since we are interested in finding the 
clear existence, or lack thereof, of a band with both GFP and hydrazide modification, we 
ran another gel from a separate but identical experiment, using 1/10th the amount of 
protein. That gel was imaged using the same technique as previously. Figure 6.5A is the 
unaltered image, demonstrating AlexaFluor® coupled hydrazide fluorescence. Lanes 2 
and 3 are from the incorporation + pketo and the peGFP-N1 + pketo conditions, and 
they were both treated with hydrazide. At the bottom of this gel, there is a dark band 
corresponding to un-reacted hydrazide which did not dialyze out, but electrophoresis 
effectively separated it from the rest of the cell lysate. Just below the 15 kD standard 
band, there is dark, heavy band indicative of a large amount of overexpressed protein 
creating a bubble. If this band had corresponded to the molecular weight of GFP, it 
might have indicated successful site-specific incorporation of pketo in response to 
amber stop codon suppression. Unfortunately, it does not correspond to the molecular 
weight of GFP, rendering this particular experiment of very little value. Since hydrazide 
can react with various types of carboxyl groups, it can react with multiple proteins in the 
cell lysate. If this experiment had used purified GFP instead of lysate, it might have given 
more information and conclusively indicated presence or absence of pketo, even if the 
yield was low. Since the western blot in Figure 6.5D shows no GFP, it is unsurprising that 
the hydrazide staining was not localized in a band corresponding to GFP. 
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Figure 6.5: [A-C] Fluorescence scan of SDS-PAGE gel used to separate 
hydrazide labeled proteins (1) Cell lysate from non-orthogonal 
tRNA condition (2) hydrazide modified cell lysate from 
incorporate + pketo condition (3) hydrazide modified cell lysate 
from peGFP-N1 + pketo condition. Scans were acquired with a 
Typhoon Trio scanner with 532 nM excitation, a 610nm 
bandpass filter, and power set to 400 V. (A) unaltered image (B) 
Image inverted, contrast increased (C) image inverted, exposure 
increase 8X using Adobe Photoshop.  [D] Western blot detecting 
GFP expression, from the same gels shown in A-C. 
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CONCLUSION 
In the preceding pages, data has been presented indicating that the function of 
the M. jannaschii based pketo specific amber suppressor tRNA/chimeric RS pair is 
compromised as compared to the function of the previously evolved pketo specific RS. 
Testing of this system in stem cells revealed unexpected fluorescence intensity increases 
caused by expression of the M. jannaschii chimeric pketo specific RS as well as 
decreases in fluorescence intensity upon addition of pketo to the media of amber 
suppressor tRNA synthesizing cells. Figure 6.4 and Figure 6.5 do not provide conclusive 
evidence of site-specific pketo incorporation. Further, the inability to detect GFP 
expression from non-orthogonal tRNA synthesizing cells or pketo incorporating cells 
indicates that larger amounts of cells and possibly protein purification will be necessary 
to detect GFP expression and/or pketo incorporation. Thus, the system needs further 
refinement before it can be successfully applied to the incorporation of UAAs in P19s or 
stem cells. The most direct approach is probably directed evolution using library 
screening in yeast to create UAA specific RSs from whole enzymes as opposed to the 
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A Mammalian Two-Hybrid System for Use in P19 Embryonal Carcinoma 
Cells 
INTRODUCTION 
We have previously described the development of a tetracycline repressor-based 
mammalian two-hybrid (trM2H) system (1), and in an attempt to further the field of 
protein-protein interactions (PPIs) studies in stem and pluripotent cell lines, we chose to 
optimize it and apply it to the study of PPIs in P19 embryonal carcinoma cells (P19s). 
This system was briefly discussed in Chapter Two, but a few more details of the system 
will be outlined below, after which optimization of the system for use in sensitive cell 
lines will be described. Finally, the use of this system in P19s will be discussed. 
The previously developed trM2H is based upon the highly active tetracycline 
repressor (TetR), a dimeric transcriptional regulator which binds specifically to the tet 
operator (TetO) to inhibit expression of a downstream gene. It was developed by 
modification of the commercially available Tet-Off® Advanced Inducible Gene 
Expression System (Clontech, Mountain View, CA).  The Tet-Off system is composed of 
the full length TetR C-terminally fused to three transcriptional activation domains from 
the herpes simplex virus VP16 (1). TetR-VP16 fusion protein dimerization allows the 
TetR dimer to bind the Tet-Responsive-Element (Tre) while the VP16 domain recruits 
transcriptional machinery.  My colleagues replaced the TetR c-terminal dimerization 
domain (alpha8-alpha10) with bait and prey molecules, shown in Figure 7.1A. When bait 
and prey proteins interact, the reporter protein, GFP in this case, is expressed (Figure 
7.1C). This system was successfully used to assess interactions of peptide pairs with 
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weak binding constants (1). Due to the sensitivity of this system, it was a good candidate 
for testing in P19s. Thus it was tested in P19s using the transfection methods described 
in Chapter Three. 
 
 
OVERALL EXPERIMENTAL DESIGN 
P19 embryonal carcinoma cells were transfected with the components of the 
previously developed trM2H system, and its function was assessed using fluorescence 
microscopy and fluorescence activated cell sorting (FACS). 
Figure 7.1 Basics of the trM2H system (A) replacement of dimerization domain with 
bait and prey molecules (B) bait/prey that do not interact will not cause 
GFP expression (C) interacting bait and prey turn on GFP expression 
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MATERIALS AND METHODS 
Routine Cell Culture 
P19 embryonal carcinoma cells were obtained from American Type Culture 
Collection (ATCC). Cells were routinely maintained in Alpha-Mem (HyClone, Logan, UT) 
with 10% (v/v) fetal bovine serum (Atlanta Biologicals, Lawrenceville, GA) and 
nonessential amino acids (Sigma-Aldrich, St. Louis, MO) in a humidified incubator at 37° 
Celsius with 5% CO2 atmosphere. Cells were passaged every 1-3 days at a ratio between 
1:4 and 1:20. For passaging, cells were rinsed in phosphate buffered saline (PBS) (Sigma-
Aldrich, St. Louis, MO), incubated with  0.5% trypsin (Gibco, Invitrogen, Carlsbad, CA) for 
3-5 minutes, and centrifuged to pellet. Cells were then resuspended in complete media 
(as described earlier in this paragraph) and seeded into clean flasks with fresh media. 
DNA Constructs 
The plasmids pTet-Off and pTRE-Tight-AcGFP were purchased from Clontech 
(Mountainview, CA). 
Electroporation 
P19 embryonal carcinoma cells at 80% - 90% confluency were harvested using 
the same procedure as used for passaging, washed once with PBS (Sigma-Aldrich, St. 
Louis, MO), spun down again, and resuspended in 600 µL of PBS per harvested T-75 flask 
of cells. For each condition in an experiment, 200 µL of cells was aliquotted into an 
eppendorf tube. Then DNA appropriate for each condition was added to the cells. The 
total volume for each electroporation was then brought up to 450 µL by addition of PBS. 
Cell DNA mixtures were then transferred to electroporation cuvettes with a 2 mm gap 
(Fisher Scientific, Waltham, MA), and cuvettes were incubated on ice for no less than 5 
minutes and no more than 15 minutes before electroporation. Cell-DNA mixtures were 
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electroporated using a Bio-Rad Gene Pulser with capacitance extender and pulse 
controller (Bio-Rad, Hercules, CA) with settings of 270 Volts, 100 Ω, and 960 µF. After 
electroporation, cells were incubated on ice for at least 3 minutes and then 
resuspended in complete media. Cells were then plated in tissue culture vessels of the 
appropriate size (Corning, Lowell, MA). Media was changed 24 hours post-transfection 
and every 24 hours thereafter until experiments were completed. 
FugeneHD Transfection 
FugeneHD was purchased from Roche (Switzerland). P19s were grown to 50-60% 
confluency in 6-well plates (Corning, Lowell, MA) and then transfected with the 
components of the trM2H system. FugeneHD was used for transfection, and complexes 
were formed in Opti-Mem using a ratio of 2 µL FugeneHD to 1 µg DNA. Media was 
changed every 24 hours after transfection.  
Hybrid FugeneHD + Electroporation Transfection 
Fugene HD was purchased from Roche (Switzerland). A modified version of 
Roche’s FugeneHD protocol was used for the hybrid transfection procedure. Instead of 
50 µL of diluent per µg of DNA, 25 µL of diluent was used per µg of DNA. Assuming the 
concentration of DNA were 1 ug/µL, the following protocol would be used. First, PBS is 
added to an eppendorf tube such that the final volume of PBS + DNA + FugeneHD will be 
25 uL/ug DNA. In this case that is 330 µL of PBS. Then 15 ug of DNA is added to the PBS, 
followed by 30 µL of FugeneHD. The tube is closed securely, vortexed, and incubated 
while cells are harvested. P19s at 80-90% confluency are harvested from a single T-75 
flask, washed in PBS, spun down, and resuspended in 900 µL of PBS. 300 µL of the cell 
solution is then aliquotted into an eppendorf tube and spun down. Once the 
supernatant has been aspirated from the eppendorf tube of P19s, the FugeneHD 
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complexes should have been incubating for about 15 minutes. Once the FugeneHD 
complexes have incubated at room temperature for at least 15 minutes, the P19 cell 
pellet in the eppendorf tube is resuspended in Fugene complexes and transferred to an 
electroporation cuvette. 
RESULTS AND DISCUSSION 
trM2H Testing With Adherent FugeneHD Transfection 
Before the stem cell transfection optimization had reached a definite conclusion, 
the trM2H was tested in P19s using adherent FugeneHD transfection. pTRE-Tight AcGFP 
was used as a negative control, pTet-Off was served as the positive control, and the 
homo-dimerizing construct gcn4 and its non-dimerizing mutant gcnxx were used to test 
the functionality of the system in P19s. The gcn4 construct proved to be the easiest to 
detect in previous experiments with HEK293T cells, so we posited that testing with gcn4 
would give a quick assessment of the viability of this technique in P19s.  
Figure 7.2 above demonstrates the inefficacy of the trM2H system in initial 
experiments. Since the pTetOff positive control failed to produce a significant number of 
Figure 7.2: Fluorescence microscopy images of P19s expressing dimerizing and non-
dimerizing trM2H proteins. pTRE-Tight-AcGFP is a negative control, while 
pTetOff is a positive control. Gcnxx is a non-dimerizing protein, which should 
not cause GFP expression, and gcn4 is a homodimerizing protein which 
should cause GFP expression. All images were taken 48 hours post-
transfection with exposure of 1 second and gain set to 1. 
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fluorescent cells, we posited that transfection efficiency was limiting the use of this 
system in P19s. Previous experiments in HEK293T cells yielded pTetOff positive controls 
with GFP expression levels similar to those of plain peGFP-N1 positive controls, around 
80-95%. This is in stark contrast to the very low GFP expression level shown in the 
pTetOff frame of Figure 7.2. Thus, we attempted to optimize transfection efficiency with 
FugeneHD by simply using 2-4 times the amount of DNA complexes to test the system 
again, but this did not increase transfection efficiency or the rate of appearance of 
fluorescent cells in positive controls or conditions with homodimerizing proteins. 
Therefore electroporation was explored as a way to increase transfection efficiency and 
enable the use of the trM2H in P19s. 
trM2H Testing With Electroporation 
P19s were electroporated with the components of the trM2H system according 
to the protocol on page 149. Figure 7.3 below demonstrates the results of that 
Figure 7.3: Fluorescence microscopy images of P19s expressing dimerizing and non-
dimerizing trM2H proteins after electroporation. pTRE-Tight-AcGFP is a 
negative control, while pTetOff is a positive control. Gcnxx is a non-
dimerizing protein, which should not cause GFP expression, and gcn4 is a 
homodimerizing protein which should cause GFP expression. There were no 
fluorescent cells in the pTRE-Tight-AcGFP well, one in the gcnxx well, and 
eleven in the gcn4 well. The pTetOff well had too many fluorescent cells to 
count by hand. All images were taken 48 hours post-transfection with 
exposure of 1 second and gain set to 1. 
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experiment. As stated in the figure caption, the gcnxx condition had a single fluorescent 
cell in the well, while the gcn4 condition had 11 fluorescent cells. If subjected to a more 
quantitative fluorescence assessment, this experiment might have yielded a signal-to-
noise ratio analogous to that achieved in HEK293T cells, in which case this system would 
be an excellent tool for the investigation of PPIs in pluripotent cell lines. Unfortunately 
fluorescence microscopy was the only fluorescence assessment method available to us 
at the time. Since the method of counting fluorescent cells by hand was time consuming 
and certainly not cost-effective in terms of man-hours spent versus information 
generated, the trM2H was not further tested until FACS sorting was available, and the 
hybrid FugeneHD + electroporation method was developed. 
trM2H Testing With FugeneHD + Electroporation 
Figure 7.4 below demonstrates the infeasibility of using the trM2H system in its 
current state to study PPIs in P19s or other pluripotent cell lines. The positive control 
yielded 1% fluorescent cells, which is barely more than twice the signal from the 
negative control pTRE-Tight-AcGFP. Similarly disappointing were the percentages of 
fluorescent cells for gcnxx, fosjun, and fosjunmu conditions as there was little difference 
between all three, and in fact a nondimerizing fosjunmu condition exhibited more 
fluorescent cells than the dimerizing fosjun condition. These results indicate that the 
data in Figure 7.4 is little more than noise. Thus, we concluded that the trM2H may be 
driven by tightly regulated promoters which cause very low levels of protein expression 
in P19s, making it nearly impossible to use this system as a means of investigating PPIs 






Though use of the trM2H has successfully detected low affinity PPIs in HEK293T 
cells (1), it does not function in P19s as well. This may be caused by poor protein 
expression in P19s in response to the trM2H’s tightly regulated promoters, indicating 
that the emphasis of the trM2H system on decreasing noise may in fact be preventing 
its function altogether in P19s. While the trM2H does not appear at this time to be a 
viable technology for use in P19s or other pluripotent cell lines, that is not to say that 
other two-hybrid systems could not produce high quality data in this cell line. It is 
possible that other systems with lower signal to noise ratios than the trM2H could 
Figure 7.4: Percentage of P19s expressing GFP as a result of dimerization of trM2H 
proteins, as determined by FACS. 
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Facilitating Protein-Protein Interactions Studies in Stem Cells with UAA 
Incorporation and a Mammalian Two-Hybrid System: Conclusions and 
Future Directions 
INTRODUCTION 
In Chapter Two the many uses and possibilities of stem cells for research and 
therapeutic applications were discussed. It was also mentioned that many promising 
lines of stem cell research are based upon incomplete knowledge of the biological 
processes underlying differentiation, dedifferentiation and tumorigenesis. Protein-
protein interactions (PPIs) studies could yield a wealth of useful information about those 
processes and facilitate better, more efficient manipulation of stem cells, thus paving 
the way for swift development of stem-cell based therapies. In order to facilitate the 
process of studying PPIs in stem cells, the aim of this dissertation has been to develop 
tools appropriate and efficient for studying PPIs in P19 embryonal carcinoma cells 
(P19s), a pluripotent cell line. 
P19 EMBRYONAL CARCINOMA TRANSFECTION METHODS 
Most, if not all PPI investigations require introduction of exogenous DNA and/or 
proteins to cells. Since pluripotent and stem cell lines are difficult to transfect, the first 
part of this project involved development of protocols for efficient DNA transfer to P19s. 
In Chapter Three, multiple methods were investigated in order to find the most 
successful transfection method for use in P19s. Commercially available reagents 
Fugene6 and FugeneHD were capable of transfecting P19s, but the efficiency was low. 
Electroporation could be used to achieve high transfection efficiencies, on the order of 
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80%, but electroporation was very sensitive to several experimental parameters that are 
difficult to control including the length of time between harvest, electroporation, and 
replating. Additionally, highly efficient electroporation require milligram amounts of 
DNA for each experiment, which made this technique prohibitive for anyone, including 
us, without unlimited amounts of DNA. So electroporation was used in many of the 
experiments in this work, but we chose to investigate the efficacy of a hybrid 
transfection method involving FugeneHD complexes and electroporation. This method 
was able to increase the consistency of transfection success while at the same time 
dramatically decreasing the amount of DNA necessary for each condition. So two 
methods for efficient transfection of P19s were developed – electroporation with our 
protocol is appropriate for highly efficient transfection when large quantities of DNA are 
available, and the hybrid method is appropriate for acceptably efficient transfection 
when DNA is in limited supply. 
CREATION OF AN UNNATURAL AMINO ACID INCORPORATION SYSTEM FOR MAMMALIAN CELLS 
Chapter Four described the creation of an unnatural amino acid (UAA) 
incorporation system for use in mammalian cells. An orthogonal amber suppressor tRNA 
was created, as was an aminoacyl-tRNA synthetase (RS) capable of charging the amber 
suppressor tRNA. A reporter protein plasmid with a stop codon was also created in 
order to decrease background signal from a previous version of the same reporter 
plasmid. It is important to note that the RS was created by ‘cutting and pasting’ modular 
protein domains from both Methanocaldococcus jannaschii (M. jannaschii) and 
Escherichia coli (E. coli) based enzymes, and this system functioned quite well in 
HEK293T cells. The development of this system was recently published (1), and its 
success lead us to believe that it could be successfully implemented in P19s. 
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AMBER STOP CODON SUPPRESSION IN P19 EMBRYONAL CARCINOMA CELLS 
Since the system developed in Chapter Four worked well in HEK293T cells we 
chose to apply it to P19s in its current state and described that application in Chapter 
Five of this dissertation. We also tested an E. coli based tRNA/RS pair and a non-
orthogonal tRNA to confirm that these pluripotent cells were in fact able to synthesize 
and use exogenous amber suppressor tRNAs. Both the non-orthogonal tRNA and the E. 
coli tRNA/RS pair were able to suppress amber stop codons well in P19s, but the M. 
jannaschii pair performed poorly when used in P19s. We hypothesize that this is due to 
the chimeric nature of the M. jannaschii based enzyme, but have not been able to 
confirm that as yet. Since some of our colleagues have experienced that UAA specific 
RSs are more efficient than their canonical amino acid counterparts, we moved forward 
with both the E. coli pair and the M. jannaschii pair. 
UNNATURAL AMINO ACID INCORPORATION IN P19 EMBRYONAL CARCINOMA CELLS 
Since we already had an M. jannaschii derived RS specific for the UAA m-acetyl-
L-phenylalanine (pketo), we used it in an attempt to incorporate pketo into the protein 
produced by the plasmid 40TAG-peGFPN1. Fluorescence activated cell sorting (FACS) 
data contradicted fluorescence microscopy images so consistently that we were forced 
to recognize that this pketo tRNA/RS pair derived from M. jannaschii was exerting some 
unknown influence on fluorescence. Though we have yet to determine exactly the 
mechanism behind the fluorescence intensities measured by FACS, we have posited that 
the chimeric pketo RS may have a compromised ability to recognize the intended tRNA, 
while at the same time pketo may be used as a substrate by endogenous RSs. In the 
given time frame we were unable to further investigate the GFP range fluorescence 
phenomena exhibited by these samples, but we were able to probe for pketo 
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incorporation using hydrazide modification. Fluorescently imaged protein gels indicated 
that pketo may be incorporated at random into all proteins, in a genome-wide fashion, 
and western blots failed to detect GFP expression in all samples except the positive 
controls. This leads us to believe that the system is not yet efficient enough to detect 
reporter protein expression in cell lysate, but purification of reporter proteins from 
larger cell samples could fix this problem. Also indicated by these results is the fact that 
P19s are probably good candidates for spatiotemporal protein labeling as routinely 
performed by the Tirrell group (2).  
At the same time we were developing an E. coli based RS specific for the UAA o-
methyl-L-tyrosine. Unfortunately, the final mutations in that RS were unable to be 
completed in time to be included in this dissertation. The sum of our results in amber 
stop codon suppression and UAA incorporation in P19s is that, while definitely possible 
at this point in time, these endeavors would benefit greatly from directed evolution of 
the current RSs or new RSs. This could ensure that the UAA specific RSs are recognizing 
the intended amber suppressor tRNAs and increase the efficiency with which they 
charge those tRNAs with UAAs. This could alleviate the necessity of using such high 
concentrations of UAAs in the growth medium so that genome-wide labeling of proteins 
would not proceed as efficiently as it seems to have done in the experiments described 
herein. 
A TWO-HYBRID SYSTEM IN P19 EMBRYONAL CARCINOMA CELLS 
Though the tetracycline-repressor based mammalian two-hybrid (trM2H) system 
did work quite well in HEK293Ts (3), it was not successful in detecting protein-protein 
interactions in P19s. This may be due to the well-documented fact that undifferentiated 
cell lines frequently respond differently than terminally differentiated cell lines to 
 160 
various promoters. The trM2H uses very tightly regulated promoters, which may not 
function well in P19s. Despite its lack of success in P19s, the trM2H could be a useful 
tool if modified for use in stem cells, as could other two hybrid systems. This could be 
done by optimizing the promoters used on the bait and prey molecules as well as finding 
a better dimerization dependent promoter for use in P19s. 
OVERALL CONCLUSION 
The overall goal of the work presented in this dissertation was to facilitate the 
study and discovery of PPIs in stem and/or pluripotent cells by developing novel 
methods and tools for use in these cell types. A successful transfection method was 
created, and an M. jannaschii based UAA incorporation system was created and its use 
demonstrated in HEK293T cells. This same system did not work perfectly in P19s, but 
the number of cells successfully expressing components of this system and suppressing 
amber stop codons is certainly high enough in the stem cell and P19 community to be 
considered quite successful. While we would like to have achieved a higher efficiency of 
amber suppression with this system, we believe that the door is now quite open, and 
future work can proceed in a more directed manner now that this work has clarified the 
areas in need of improvement. 
We successfully used the E. coli based UAA incorporation system to suppress 
amber stop codons in P19s with great success, and it was incredibly regrettable that we 
were unable to incorporate a UAA using this same system. We believe the next step in 
UAA incorporation in P19s involves the E. coli pair, and that this pair will yield the 
fastest, most exciting applications of UAA incorporation in P19s at this time. Therefore 
the next logical line of work in this vein would be to finish creation of the o-methyl-L-
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tyrosine specific RS and/or to collaborate with other researchers who have already 
developed these enzymes in order to quickly exploit their utility. 
Since the overall goal of this research was to facilitate the study of PPIs in stem 
cells, we believe that goal has certainly been achieved. While this work is just beginning, 
it has the potential to greatly impact the field of stem cell science, and it is our belief 
that the work presented in this dissertation amounts to being just on the cusp of using 
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